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ABTRACT
ACROLEIN SUPPRESSES MOBILIZATION OF ENDOTHELIAL PROGENITOR
CELLS
Laura Anne Wheat Nissley
December 16th 2011

Acrolein is a common pollutant present in ambient air, automobile
exhaust, and tobacco smoke. Previous studies show that exposure to acrolein
increases cardiovascular disease risk. To determine whether acrolein affect
cardiovascular regeneration, we investigated the cardiovascular effects of
inhaled acrolein. Adult male CS7BLl6 mice were exposed to room air or acrolein
(O.S, 1 or S ppm) for and the endothelial progenitor cells (EPC) level in peripheral
blood (PB) was measured by flow cytometry. To examine the proliferative
capacity of EPCs, bone marrow cells (BMCs) were cultured on fibronectin-coated
slides. Brief exposure to acrolein (S ppm, 6h) or 4 day (1 ppm) exposure led to a
42% decrease in PB Flk+/Sca+ cells. BMCs isolated from mice exposed to
acrolein for 1d (S ppm) or 4d (1 ppm) formed more colonies than BMCs of airexposed mice. Combined VEGF-A (100 I-Ig/kg, ip, 4d) and AMD3100 (S mg/kg;
ip, last day only) treatment increased PB EPCs cells in air-exposed mice but not
in acrolein-exposed mice (1 ppm, 4d). These data indicate that circulating EPCs
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are a sensitive target of airborne pollutants and that acrolein at
concentrations encountered in tobacco smoke suppresses EPC levels in the
blood but it increases the proliferative capacity of EPCs in the bone marrow. My
thesis is that EPCs are sensitive targets for environmental insults, such as
acrolein, thus increasing the risk of developing cardiovascular disease and
endothelial dysfunction. Studies here show that the effects of acrolein on EPC
after exposure by inhalation (Aim 1), the environmental pollutant acrolein,
prevents mobilization of EPCs by cytokine stimulation (Aim 2), evaluated
perfusion recovery of hindlimb ischemia after exposure to acrolein inhalation
(Aim 3).
The results of these studies support the hypothesis that exposure to
environmental pollutant acrolein prevents EPC mobilization.
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CHAPTER I
GENERAL INTRODUCTION
ENVIRONMENTAL POLLUTION AND CIGARETTE SMOKE

The United States and other industrialized countries face an increasing

amount of air pollution and related health concerns. The World Health
Organization (WHO) data base has estimated that 1.5 billion people in the world
are exposed to dangerously high levels of pollution on a daily basis 1. WHO also
estimates 3 million deaths are attributed to outdoor air pollution and 1.6 million
deaths are attributed to indoor-air pOllution 2 . The earth's atmosphere itself is a
complex mixture of gases, changing in composition with each atmospheric layer.
However, when defining environmental pollution the two layers of concern are
the troposphere and stratosphere. The troposphere is the lowest portion of the
earth's atmosphere, it contains approximately 80% of the total atmosphere mass
and 99% of its water vapor and aerosols and the ozone layer is located within the
stratosphere.
When defining pollution Webster dictionary simply states, "pollution
is the introduction of contaminants into

a natural environment that causes

instability, disorder, harm or discomfort to the ecosystem i.e. physical systems

or living organisms". The EPA in conjunction with the Commission for
Environmental Cooperation estimates each year the United States alone spews 3
million tons of toxic chemicals into the air, water and land

3.

There are also naturally

occurring sources of pollution such as volcanic eruptions, pollen, mold, sulfur release
from oceans and forest fires

4-8.

For the most part, pollution is man-made, has many

sources and has escalated since the dawn of the industrial revolution. However,
pollution isn't just a plague of modern society even in prehistoric time man was
exposed to pollution. Scientists have found signs of indoor pollution on cave walls in
the form of soot that resulted from building fires for heating and cooking with no or little
ventilation

9.

Modern pollution can still be attributed to wood burning but also the

combustion of any petroleum product or byproduct, smelting, agriculture, cooking, coal
burning, production of plastic, foam, energy, and nuclear power; the list goes on

10-14.

Historically, pollution has been associated with severe or even life threatening health
conditions. Cigarette smoke and second hand cigarette smoke exposure is a well
publicized and published pollutant that is directly linked to the development of cancer;
but can cause asthma, emphysema, decreased birth weight, increased risk for heart
disease, stroke, coronary heart disease, and overall increased morbidity

15-19.

The EPA has classified 5 major pollutants; ozone (0 3 ), carbon monoxide
(CO), nitrogen oxides (NO), particulate matter (PM), sulfur dioxide (S02), and lead.
Each pollutant is produced from a number of sources and can have varying health
effects. Ozone is a colorless gas that constitutes photochemical smog at the earth's
surface. Ozone is formed in the lower troposphere as a result of chemical reactions
between oxygen, volatile organic compounds and nitrogen oxides in the presence of
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sunlight 20. Ozone has been associated with significant health problems including
impaired lung function, chest pain, cough and lung inflammation 21,22. Carbon
monoxide is an odorless colorless gas emitted from the exhaust of vehicles and other
kinds of engines where there is incomplete fossil fuel combustion 23. Carbon monoxide
reduces the ability of blood to deliver oxygen to vital tissues, effecting primarily the
cardiovascular and nervous systems 24-26. Nitrogen dioxide is a light brown gas that
results from the burning of fossil fuels in utilities, cars, and trucks 23. Nitrogen dioxide is
the major cause of smog, acid rain and at high levels can be harmful to not only
humans but vegetation as well 27,28. Particulate matter (PM) can be solid or liquid
droplets from smoke, dust, fly ash and condensed vapors. Particulate matter is
produced from industrial processes, smelters, automobiles, burning industrial fuels,
wood smoke, and dust from unpaved roads 29 . These microscopic particles can affect
breathing, respiratory tract health, increased respiratory disease, lung damage and
linked to increased morbidity 30,31. Sulfur dioxide is a colorless odorless gas emitted
largely from industrial, institutional, utility, and apartment-house furnaces and boilers,
as well as smelters, paper mills, petroleum refineries, and chemical plants32, 33. Sulfur
dioxide is one of the major pollutants that causes smog and can affect susceptible
individuals like asthmatics 23,34. Lead and lead compounds can adversely affect human
health by either ingestion or direct inhalation of contaminated soil, dust, paint 35.
Exposure to lead can affect mental development, kidney function, and blood chemistry
36, 37
History has shown that exposure to increased amounts of pollution can be
devastating. There have been several acute incidences displaying the effect that
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pollution has on human health, and mortality. Several cities and towns have
encountered these events first hand. Notable pollution related deaths have occurred in
the past due to weather inversions in conjunction with increased industrial activity in
low lying areas. One of the earliest recorded cases was in the Meuse Valley in
Belgium, December 1930, killing 60 and sickening another 6,000 people. Deaths were
attributed to "episodes of severe pulmonary attacks". Investigators pOinted to the
probability that sulfur dioxide (S02) or oxidation products of that compound from factory
smoke along with unusual weather patterns were the cause

38.

In 1948 over a span of 2

days the small town of Donora, Pennsylvania also suffered severe casualties. Thick
smog trapped from an iron smelting plant combined with weather inversion, was
responsible for killing 20 people and sickening 6,000 more 39. Years later in 1952,
12,000 people died and 100,000 were sickened by pollution and stalled weather
patterns in greater downtown London, England. Thousands of tons of black soot, tar
particles, and sulfur dioxide had accumulated in the air due to the heavy coal
combustion from factories along the river Thames. Estimates of PM10 concentrations
during December, 1952, range between 3,000 and 14,OOOIJ9/m3 with the high range
being approximately 50 times higher than normal levels 40,41. After this incident it
became evident the Donora disaster was just the beginning and led the United States
Congress to pass the first air pollution policy in 1955, the Air Pollution Clean Act. This
policy was later followed by the formation and implementation of the EPA in 1970 by
President Richard Nixon 42,43.
Depending on the geographic location, population density, and level of
industrialization; pollution can vary in concentration and composition. Hong Kong,
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China has a population of 7.2 million and a population density of 16,576 people/mile2 .
Hong Kong is highly industrialized with little emission control policies enforced on
industry. Therefore, it is not surprising that Hong Kong is one of the most polluted cities
in the world

44.

The major 5 recognized pollutants vary in concentration; S02 350 jJg/m 3,

PM 1BO jJg/m 3, NO 150 jJg/m 3, CO 10,000 jJg/m 3, 0 3 24 jJg/m 3 45,46. Compared to Hong
Kong, Los Angeles, California has drastically different levels of pollution. Los Angeles
has a population of 3.B million and density of 7,544 people/mile 2,California boasts
extremely strict emission control laws and has a different industrial base, which
accounts for the vast difference when compared to Hong Kong. The major 5 pollutants
in ambient Los Angeles air; S02 0.43 jJg/m 3, PM 39 jJg/m 3, NO 14.3 jJg/m 3, CO 304
jJg/m 3, 0 3 13 jJg/m 3 47,48. When levels of these pollutants reach high enough levels,
they can be hazardous or even deadly upon exposure and can cause serious health
effects with long term repeated exposure. The Occupational Safety and Health
Administration (OSHA) has compiled permissible exposure limits (PELs) for hundreds
of pollutants. Studies have found there are no real "safe" or acceptable exposure
concentrations of troposphere or ground-level ozone exposure. Overtime, exposure to
ozone will have negative health related effects, but OSHA ozone PELs is 0.075ppmlBhr
day. Sulfur dioxide PELs are not to exceed 140pbb in a 24hr period. Particulate matter
PELs are not to exceed (PM2.5) 35jJg/m3 per 24 hour period, (PM10)150jJg/m 3 per 24
hour period. Acceptable nitric oxide exposure levels have become more stringent,
individuals are not to exceed 1OOppb/hr of exposure. Carbon dioxide standards allow
individual exposures to reach 9ppmlBhr day. OSHA has found these safety standard
exposure levels to have no long-term health effects. However, data now show for every
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10jJgI m3 of city specific particulate matter2.5 the mortality ratio rate (RR) is 1.13,
demonstrating an inverse correlation between pollution levels and mortality 49,50.
Environmental tobacco smoke (ETS) is a pollutant associated with
severe health consequences. Smoke from cigarettes is a complex mixture of
4,000 different chemicals; 50 known carcinogens; 200 known poisons. ETS is
made up of a combination of side stream and mainstream cigarette smoke. Side
stream cigarette smoke is smoke coming off the end of a smoldering cigarette.
Mainstream smoke is considered active smoking, the combination of inhaling and
exhaling after taking a puff on a lit cigarette. The frequency of puffs, duration and
volume all contribute to the make-up of mainstream smoke 51 , 52. Each of the
chemicals in cigarettes varies depending on brand and country of origin (Table 1)
53-57. Studies have shown that exposure levels increase significantly from
mainstream smoke to side stream smoke, particulate matter significantly
increases by 5 fold like58 . Even though combustable tobacco products are full of
numerous chemical aldehydes are highly reactant and abundant within cigarette
smoke (Table 2). Even though acrolein is not necessarily the most prevalent of
the aldehydes it is one of the most reactive.
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Table 1: Cigarette chemical content (one burned cigarette)
Brand

Acrolein

CO Nicotine Tar

53-57

Country or
origin

Merit

631-1g

9

0.8 mg

10 mg

USA

Marlboro

1551-1g

10

1.8 mg

12 mg

USA

Camel

1491-1g

16

1.1 mg

15 mg

USA

Sakura

350 l-lg

18

2.0 mg

26 mg

Japan

Table 2: Aldehyde content cigarettes (US Dept of Health and Service)

Aldehyde

Amount per cigarette

aceta Ie hyde

1.4mg

crotonaldehyde

0.21-1g

formaldehyde

1.61-1g

7

Exposure to ETS whether it is from actively smoking or from second hand
exposure is a major cardiovascular risk factor

59,60.

The WHO estimate over 26.5

% of males and 22.1 % or females in the world actively smoke; while 43 % of the
world's children are exposed to second hand smoke

61.

Every year 5 million

active smokers die, while 600,000 people exposed to second hand smoke also
succumb to smoke related illnesses

62.

Cigarette smoke is associated with

endothelial dysfunction, decreased angiogenesis, increased arteriosclerosis and
various other cardiovascular diseases

18,63,64.

Nevertheless, the specific

chemicals in the tobacco smoke that cause toxicity have not been identified and
the mechanisms underlying the cardiovascular toxicity of tobacco smoke remains
unclear. The main questions remain what chemical(s) constituents,
mechanism(s) and susceptibility factors associated with ETS and environmental
pollution can account for increased mortality and decreased cardiovascular
health.
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Acrolein

Acrolein is an unsaturated aldehyde also known as acrylaldehyde, acrylic
aldehyde, allyl aldehyde, ethylene aldehyde, 2-propenal, and prop-2-en-1-al.
Acrolein at room temperature is a colorless or yellow combustible liquid.
Structure:

H

\

/

H

P

#

C=CH-C

\

H

Molecular weight: 56.06 gtmol
Vapor pressure: 274 mmHg
Conversion factor: 1 ppm

=2.3 mgt m3 ; 1mgt m3 =0.44 ppm

Acrolein is used in industry for the production of plastics, rubber and as an
intermediate in the production of acrylic acid. Acrolein is also used as an
herbicide, aquacide, slimicide; on farms, in drainage ditches and in paper
production. Acrolein is also present in varying concentrations as a result of
combustion of organic material (Table 3)

65-67.

Acrolein is highly water soluble

and possesses low vaporizing pressure making acrolein a highly mobile
substance. In ambient air acrolein ecxist solely in a vapor-phase, and exposure
occurs primarily through atmospheric contact. For long-term outdoor pollution
studies, government agencies use TO-11A method (active sampling with 2-4
dinitrophynlhydrazine [DNPH] coated solid sorbents). This particular method
9

samples air downstream of KI oxidant scrubbers which then pass on to silica gel
cartridges coated with DNPH, DNHP derivatives are analyzed by liquid
chromatography (LC) with detection by diode-array, UV-visible spectroscopy.
The DNHP method is unstable with humidity, temperature and ozone level
fluctuation. This method is used primarily on the west coast and mid-west
regions. The most recent and highly stable system for collecting airborne
aldehyde and ketone data is the modified passive aldehyde and ketone sampler
(PAKs). PAKs method for collection effeciencys is -100% for most saturated
carbonyls, and 99±S% for acrolein even with humidity fluctuations from 30-90%.

(Table 4).
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Table 3: Sources and level of acrolein emissions
Amount

Source
Gas engine exhaust

0.05-27.7 mg/m~

Diesel engine exhaust

0.12-0.21 mg/m 3

Smoky indoor environment

2.3-275 IJg/m 3

Residential wood stoves

0.7-6.0 IJg/m 3

Main stream cigarette smoke (exhaled

10-140 IJg/m~

smoke)
100-1700 IJg/m

Side stream cigarette smoke
(smoldering ash)

208,1081bs

Total industrial air emissions

6.9 mg/m~

Fires (Boston, USA)

11

3

Table 4: Methods for acrolein sampling and testing. a .b
Sample
matrix

Sample preparation

Air

Adsorb on sorbent coated with 2(hydroxymethyl)piperidine on
XAD-2; desorb with toluene;
analyse for oxazolidine derivative
Draw air through midget impinger
containing acidified DNPH and
isooctane; extract DNPH
derivative with
hexane:dichloromethane (70:30)
solution; evaporate to dryness;
dissolve in methanol
Draw air through bubblers in
series containing 4hexylresorcinol in an alcoholic
trichloroacetic acid solvent
medium with mercuric chloride
Draw air through midget impinger
containing 1% sodium bisulfite;
react with 4-hexylresorcinol in an
alcoholic trichloroacetic acid
solvent medium with mercuric
chloride
Collect in DNPH-impregnated
adsorbent tubes (with calcium
chloride tubes); extract with
acetonitrile
Derivatize with O-benzylhydroxylamine to O-benzyloxime;
brominate with sulfuric acid,
potassium bromate, and
potassium bromide; reduce with
sodium thiosulfate; extract with
diethyl ether
Derivatize with 0-(2,3,4,5,6pentafluorobenzyl)hydroxylamine

Moist air

Exhaust
gas

Aqueou
s
solution
Rainwat
er

Liquid
and
solid
wastes

Derivatize with O-methoxylamine
to O-methyloxime; brominate with
sulfuric acid, potaSSium bromate,
and potassium bromide; reduce
with sodium thiosulfate; elute with
diethyl ether
Purge (inert gas); trap in suitable
adsorbent material; desorb as
vapour onto packed gas
chromatographic column

12

Assay
procedure

Limit of
detection

Reference

GC/NSD

2 jJg/sample
(6.1 jJg/m 3 )

US OSHA,
1989; Eller,
1994

Reversedphase
HPLC/UV

NR

US EPA,
1988

Colorimetry

22.9 jJglm
(10 ppb)C

Colorimetry

22.9 jJg/m'

j

(10 ppb)

HPLC/UV

Feldstein
et aI.,
1989a

Feldstein
et aI.,
1989b

GC/ECD

0.3
jJg/sample
(0.01
mg/m 3 )
NR

Vainiotalo
&
Matveinen,
1992
Nishikawa
et aI.,
1987a

MIMS/EIM
S

10 jJg/litre
(10 ppb)

Choudhury
et aI., 1992

GC/ECD

0.4 jJg/I itre

Nishikawa
et aI.,
1987b

GC/FID

0.7 jJg/litreO

US EPA,
1986

Biologic
al
samples

Oerivatize with ONPH; extract
with chloroform, hydrochloric
acid; dry with nitrogen; dissolve in
methanol

HPLC/UV

1 ng

Boor &
Ansari,
1986

a

From IARC (1995).

b

Abbreviations used: ON PH = 2,4-dinitrophenylhydrazine; ECO = electron capture
detection; FlO

=

flame ionization detection; GC

=gas chromatography; HPLC/UV =

high-performance liquid chromatography/ultraviolet detection; MIMS/EIMS =
membrane introduction mass spectrometry/electron impact mass spectrometry;
MS

=mass spectrometry; NR =not reported; NSO =nitrogen selective detection.

c

Note that 1 ppb = 1 x 10-9 .

d

Practical quantification limits for other matrices: 7 jJgllitre for groundwater; 7 jJg/kg for
low-level soil samples; 350 jJgllitre for water-miscible liquid waste samples; 875jJg/kg
for high-level soil and sludge samples; 875jJgllitre for non-water-miscible waste samples.
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The EPA reported mean ambient concentrations of acrolein to be 14.3I-1g/ m 3 (6
ppb) (Table 3)

65-67.

Not only can we breath in acrolein we can also ingest acrolein, through heating of
carbohydrate-containing foods which results in the formation of reactive
carbohydrate intermediates that can undergo carbon-carbon cleavage and
ultimately produce acrolein 68 . Acrolein is a highly reactive electrophile due to the
polarization of the double bond by the aldehyde group. In the body acrolein
reacts readily with protein nucleophiles, non-protein sulfhydryl groups, or primary
and secondary amines found in nucleic acids. Acrolein is endogenously
produced as a by-product of lipid peroxidation and possible mediator in several
human diseases, as reviewed by Uchida et at .,69,

70

Acrolein conjugates readily

and rapidly with sulfhydryl groups and is essentially irreversible. This reaction
leads to the formation of thiazolidine derivatives and a decrease in glutathione
(GSH) stores without an increase in oxidized GSH (GSSG). This pathway results
in an acrolein-GSH adduct which is further metabolized by both mitochondrial
and cytosolic aldehyde and alcohol dehydrogenase. Ultimately acrolein is
excreted in urine as mercapturic acid derivatives, or remains as protein-acrolein
adducts within the body (Fig. 1) 67,71
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Figure 1
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Figure 1 metabolism of acrolein Intermediary metabolism can form Acrylic acid
or Glycidaldehyde from acrolein, acrolein can also be excreated in the urine as
mercapturic acid derivatives goes through several
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It has been previously shown that administration of radioactive acrolein (0.82
mg/kg) to lactating goats, incorporation of the radioactivity appeared to follow
incorporation of metabolites into normal biosynthetic pathways of both mother
and nursing kid

72.

Acute exposure to acrolein at levels as low as 0.99_ppm for 5 min
causes severe eye and nose irritation in humans

73,74.

Lyons et a/.,

75

showed in

a multi-species study containing fifteen Sprague-Dawley rats (male), seven to
eight Princeton or Hartley guinea pigs (male), two pure bred beagle dogs (male);
and nine squirrel monkeys (male). All species were exposed to acrolein, 8 hr/day,
5 days/week, for 6 weeks at concentrations of either 0.7ppm or 3.7ppm. No
deaths were reported in the 0.7ppm group, histopathology of the lungs showed
significantly increased inflammation in all species, however inflammation was
found to be significantly more chronic in the lungs of more complex organisms;
beagles and monkeys. In the 3.7ppm group, two monkeys died within two weeks
after onset of exposure. All species exhibited extensive mucosal gland irritation
within the first week which continued throughout the remainder of the study. In
histological sections non-specific inflammatory changes were noted in the lungs,
liver, and kidney of all species inflammatory changes within the lung were seen in
the bronchi rather than the bronchioles. All study groups were found to be
significantly different from that of control groups. Data supports acroleins ability
to cause extreme tissue inflammation and damage not only in the lungs but can
travel to various organs throughout the body and inflammation severity varies
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from species to species. The more complex organisms seemed to be more
susceptible to inflammation caused by acrolein inhalations.
Acrolein is classified as an environmental toxicant, the defined OSHA
permissible exposure limit is 0.1 ppm per 8 hi d (time weighted average;TWA) or
0.3ppm for 15 min. short term exposure (TWA). Both are near or above acrolein's
odor threshold of 0.2ppm.Acrolein can cause disruptions in sulfahydryl groups
that are critical for chemical reactions within living cells, leading to disruption of
intermediate metabOlism, inhibition of cell growth or division, and cell death

76.

Acrolein is a known constituent of environmental tobacco smoke (ETS); ETS
promotes arteriosclerosis and endothelial dysfunction by inducing
proinflammatory stimuli. The link between cigarette smoke and cardiovascular
disease is poorly understood, however due to the abundance, reactivity, and
proinflammatory nature, acrolein is a likely candidate

77.

There is a need to

further understand acroleins possible role in cardiovascular disease and the link
between cigarette smoke. The CDC reports people that smokers are 2-4 times
more likely to develop coronary heart disease compared to non-smokers.

Endothelial Progenitor Cells

Prior to 1997, angiogenesis was thought to occur only in a neonatal state, as
mesodermal cells differentiated into angioblasts, ultimately giving rise to
endothelial cells, the process of neovascularization. However, in 1997 Asahara
and colleagues revolutionized this dogma with the discovery of CD34 + cell subset
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that possessed an endothelial phenotype. The endothelial like cells were sorted
from human blood by magnetic beads and autologous transplants showed these
cells had the ability to incorporated into sites of active angiogenesis and were
beneficial in wound healing, they coined these cells Endothelial Progenitor Cells
(EPCs) 78.

Definition:
EPCs originate from the bone marrow (8M) and are present in either a quiescent
state in the non-vascular niche of the 8M or a proliferative state in the vascular
niche from which they are mobilized79, 80. EPCs can be defined by numerous
markers in varying combinations, the most accepted is a combination of a stem
cell marker along with an endothelial lineage marker. In the initial paper Asahara
et. aI., human blood was drawn, sorted by magnetic bead for CD34+ and Flk-1+
cells, then stained for CD45, CD34, CD31, Flk-1, TIE-2 and E-Selectin 78 . There
are several markers commonly used to discern EPCs from other cells present
within the body (Table 5) 81,82.
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Table 5: Commonly used EPC markers and definition
Definition
Endothelial marker, surface receptor
for VEGF (mouse)

Marker
Vascular Endothelial Growth Factor
Receptor 2+
(VEGFR2, KDR, Flk-1)
von Willibrand factor (vWft

Endothelial marker, cell surface
marker bind to Factor VIII, important
for platelet adhesion to wound sites
(mouse)
Hematopoetic stem cell lineage
marker, important for cell-cell
adhesion (human)
Cocktail of antibodies used to
determine cellular lineage (human)
Surface marker on hematopoetic
cells, protein tyrosine phosphatase
(mouse)
Also known as Prominin, cell surface
marker of unknown function (mouse)
Cell surface sugar binding protein
(mouse)
Stem cells marker-1, glycosyl
phosphatidylinositol-anchored cell
surface protein (mouse)
Cytokine receptor, binds to stem cell
factor
Endothelial specific, identified as
Angiopoietin I receptor (mouse)
CXC chemokine receptor, bind SDF1Jmousel

CD34+

LinCD4S-1o,m

CD133+
Lectin+
Sca-1+

C-kit+
Tie-2+
CXCR4+
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EPCs are evaluated by surface markers and angiogenic ability when seeded on
Mitrigel®. Angiogenic ability of these cells allow for increased repair of damaged
vasculature and improves over all vascular health. Other endothelial properties
have been evaluated on EPCs as well such as, NO production which is very
important for vasodilation and further EPC homing to sites of injury. It has been
shown circulating endothelial progenitor cells account for only 0.01 % of
circulating cells. However, three hours after hypoxic injury, circulating EPCs are
visibly increased, and by 24 hours they account for 12 % of Circulating cells

83 .

Mobilization:
Found within red bone marrow is a heterogeneous population of cells that make
up the stem cell niche, consisting of fibroblasts, osteoclasts, hematopoietic and
endothelial cells. The bone marrow stromal cells that line the inside
microenvironment of the bone marrow are responsible for providing extrinsic
signals that maintain the stem cell niche and regulate the repopulation of stem
cells

81,84.

While attached to the stromal cells, stem cells are maintained in the Go

phase of the cell cycle, which is the quiescent non-proliferative phase.
Endothelial progenitor cell mobilization from the bone marrow occurs when
cytokines interact between the bone marrow stromal cells and stem cells. This
allows stem cells to disengage the bone marrow and pass into the blood stream.
Respectively, during hypoxic injury, the Hypoxia Inducible Factor 1-0 (HIF1-0)
protein levels increase and cause up regulation of VEGF levels. Bone marrow
stromal cells can bind to VEGF and increase production of nitric oxide (NO), NO
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can then increase active-MMP-9 levels. MMP-9 is responsible for cleaving
membrane bound kit ligand (mKitl), and thus, increasing the bioavailability of
soluble kit ligand (sKitl). After levels of sKitl increase attached endothelial
progenitor cells bind sKit and are pushed from a quiescent state into a
proliferative state. Studies have concluded EPCs follow SDF-1/CXCR4 axis and
gradients within the circulation (Scheme 1) 81,84-87.
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Scheme 1: Hypoxic injury and mobilization of EPCs from bone marrow
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Recruitment/homing:
Stromal Derived Factor 1 (SDF-1) protein is crucial for homing and recruitment of
circulating EPC to sites of injury. SDF-1 has chemotactic activity that controls
adult stem cell trafficking and is the ligand for G-protien coupled receptor
CXCR4 88 . EPCs possess CXCR4 receptors and it has been shown local
administration of SDF-1 at the sites of injury increases therapeutic
neovascularization

89.

With injury to the endothelium VEGF levels steadily

increase along with numerous other cytokines and chemokines. Various stimuli
promote mobilization and recruitment of EPCs to sites of injury

90.

Once

circulating EPCs come into contact with the appropriate recruitment stimulus,
surface adhesion factors are thought to be upregulated and help with cell
recruitment and cell adhesion (Table 6)

90-97.
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Table 6: EPC homing factors
Chemokinel receptor

Cell type and markers

Animal model (species)

EPC, CD34+

Hind limb ischemia

and integrins
SDF-1/ CXCR4

(Murine)
IL-8 ICXCR2 or CXCR 1

CD34+

Myocardial infarction
(Murine)

HMGB-1

Myocardial infarction

EPC

(Murine)
J32-integrin

EPC

Myocardial infarction,
Hind limb ischemia
(Murine)

E- and P- Selectin

EPC

Tumor, Hind limb
ischemia
(Murine)

25

Transmigration:
EPC transmigration is similar to leukocyte rolling and transmigration. In Vitro
studies have lead to evidence suggesting once the EPC has made contact with
or near the injured tissue, low affinity contacts are made between selectins
present on the cell surface and the vascular wall, much like the process seen
with leukocyte rolling 98 . The integrin, E-selectin, is important to not only homing
but actually regulating the bone marrow-derived EPC recruitment to sites of
injury. After cell rOlling, further adhesion occurs through ~2-integrins99,
firm adhesion

a4~1

100.

For

integrins and LFA-1 increase adhesiveness via their

respective ligands, VCAM-1 and I-CAM-1. After rolling and firm adhesion, EPCs
must transmigrate, however, little is known about the true mechanism behind this
process. It is postulated that PECAM-1 and CD99 playa role in transmigration of
EPCs (Scheme 2)101.
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Scheme 2: EPC adhesion and transmigration
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Differentiation:
After activation and mobilization into the circulation, EPCs start maturing and
eventually loose stem cell markers and characteristics while simultaneously
acquiring more mature endothelial cell characteristics 102. In previous studies it
has been shown phospho-Akt is induced in the ischemic muscle by cytokines
such as VEGF and SDF-1, which are secreted by skeletal muscle cells, stromal
cells, and endothelial cells in response to ischemia. In particular, the
phosphorylation of Akt in endothelial cells leads to entrapment of systemically
administered ex vivo-expanded EPCs into the ischemic muscle through various
kinds of mechanisms, overexpression of ICAM-1 on endothelial cells (ECs) and
the increased incorporation and transendothelial migration of EPCs 103. In order to
study actual incorporation, EPCs were isolated and tagged with diacyl-LDL then
injected into nude mice. Histology sections were taken of ischemic muscle and
56 ±4.7 % of the vessels had EPC incorporation out of the 16 section evaluated
(1 OX field) 103. While still other studies using the same approach show only 0.01 %
of EPCs injected going to the site of injury and actively participate in
angiogenesis 104. Various studies report different incorporation numbers for EPCs
at the sites of injury, this could be accounted for by the methods used and the
analysis of data. There is are small amounts of EPCs in the circulation even after
ischemic injury and so far histology and rudimentary counting has been the main
published method, a lot could be missed or over counted by this approach just
due to human error or bias.
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When incorporated into the site of injury, EPCs act in a paracrine
fashion releasing growth factors such as VEGF and stimulating release of NO,
thus stimulating the release of growth factors from surrounding adult endothelial
cells. The growth factors released recruit more EPC to the site of injury and
other pro-angiogenic cells such as macrophages. The immature EPCs soon fully
differentiate into mature endothelial cells, after exposure to growth factors such
as VEGF, SDF-1, IGF-1, and HGF in the surrounding environment

91, 105-108.

Non-Bone Marrow, Endothelial Progenitor Cell Niches

EPC can also be found in resident tissue niches outside of the bone marrow.
Stem cell niches provide a balance between quiescence and activity of the stem
cell by protecting them from differentiation stimuli, apoptotic stimuli, and other
stimuli that could challenge stem cell reserves. A stem cell niche is defined by
functional dimensions and anatomical dimensions which specifically enable stem
cells to asymmetrically reproduce and allow for self renewal

109-111.

Stem cells

within a niche are embedded in a 3-D extra cellular matrix (ECM). The ECM can
be divided into two groups, structural proteins and proteoglycans (PGs), including
glycosaminoglycans (GAGs), which are primarily responsible for regulatory
processes in disease and development. The ECM of the stem cell niche consists
mainly of basement membrane components, such as collagens, laminins,
fibronectin, and GAGs. Integrins connect the ECM niche to the internal
cytoskeleton of the stem and progenitor cells and they transmit external signals
directly to the stem cells. When mechanical force is applied to the ECM, this
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influences the integrins and impacts stem cell fate by activation of various
signaling pathways. Within each niche, some ECM proteins have specialized
functions restricted to distinct stem cell niches

112.

For example,

13-1

integrins are

predominately expressed within epidermal stem cell niches while tenascin c and
osteopontin are specifically present in hematopoietic stem cell niches. Some
investigators have suggested that bone marrow is the only source of
stem/progenitor cells, however when the body depletes the bone marrow stem
cells, non-bone marrow stem cell niches are called upon and playa vital role and
help repair damaged tissues 113. Non-bone marrow niches are found throughout
the body some are better documented and studied than others. It is thought that
niches are formed during embryogenesis and stem cell migrations during fetal
tissue development and are actually maintained into adulthood

114,115.

The spleen contains two distinct areas known as the red and white pulp,
the red pulp contains macrophages that filter out debris and dead cells from the
circulation. The white pulp or "lymphoid compartment" synthesizes antibodies
against invading pathogens and releases platelets and nuetrophils in response to
bleeding and infections 116-118. However, aside from these functions the spleen is
the site of extramedullary hematopoiesis. In times of stress and disease when
bone marrow cannot fulfill the demand for new cells, the spleen acts as a
secondary hematopoietic center 118 . This is not surprising since the spleen is a
site of hematopoiesis during gestation

104.

Recent studies have shown cells with

multi-lineage capability are found within the spleen and the spleen has been
recognized not just as a secondary center for hematopoiesis but also a storage
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site for multiple stem cell lineages. Many studies have linked this to a
developmental origin called the aorta-gonad-mesonephros (AGM)

119.

The AGM

region is the first site for hematopoiesis, which then migrates to the liver and
spleen, until ultimately the bone marrow takes over as the primary site of
hematopoiesis 120, 121. Recent studies have shown the AGM has a broader cell
lineage potential than just producing CD45+ hematopoietic cells. When CD45cells were harvested from the AGM region of mice expressing green
fluorescence protein (GFP) and transplanted into the liver of neonatal mice
124,

122-

the transplanted cells were found not only in the bone marrow and spleen but

also non-hematopoietic tissue as well- liver, kidney, lung, small intestine,
vascular wall and uterus

125-131.

Literature suggests that stem cells with multi-

lineage potential are found in the spleen as a result of early migration pattern
from the AGM region [ref]. This leads to the idea of how niches could be formed
not just within the spleen but various locations in the body due to early
gestational development and stem cell migrations along developmental axis
132.

122,

It is currently believed that tissue-specific progenitor cells reside within niches

proximal to the cells types they will regenerate.
Recent studies have led to the identification of several EPC niches in the
spleen, liver, adipose tissue, adventitial tissue, and small intestine

125-131.

Using a

parabiosis model coupled with a reverse bone marrow transplant and hindlimb
ischemia, Aicher et aI., 99 set out to discern the actually percentage of EPC that
come from non-bone marrow niches. In this study 74 ± 13% of Circulating
progenitor cells are non-bone marrow derived and incorporated into hindlimb
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ischemia (HLI) of rats. In addition as previously mentioned organs such as the
liver and small intestine have a considerable number of resident progenitor cells,
within progenitor cell niches. Sex-mismatched transplant of liver and small
intestine of rats followed by the induction of HLI, showed that 4.7 ± 3.7% small
intestine-derived endothelial progenitors incorporated in the ischemic tissue of
HLI models and contributed to vasculogenesis, while the liver contributed 6.3 ±
2.2% 133. Within the adipose tissue, there is the stromal vascular fraction (SVF).
This fraction has angiogenic capacity equivalent to that of bone marrow-derived
EPCs when injected after HLI 134.,Other studies have shown that the lung and
skeletal muscle also possess endothelial progenitor cell niches.

However, it is

unclear whether these cells are truly tissue -resident or whether they are derived
from the bone marrow 131,135. Vascular tissue itself has also -been studied and a
"vasculogenic zone" was has been recently discovered. This zone lies between
the adventitial and media of the vessel wa1l 126 . Cells within this vasculogenic
zone have been identified as CD34+/Tie2+/KDR+NE-Cadherin+ ,capable of
differentiating into mature endothelial cells and form capillary like sprouts in
Mitragel 126.
Hill et al., 136 performed a series of experiments with male patients who
had varying degrees of cardiovascular risk but had no history of cardiovascular
disease. Peripherial blood was taken and EPC numbers were significantly
reduced in patients with elevated cholesterol levels, hypertension and diabetics.
They also found a significant inverse correlation between EPC numbers and
Framingham scores of these patients. EPC depletion could be a by-product of
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increased oxidative stress or other physiologic process within the patient.
However, this decrease could also be due to continuos endothelial injury and
EPC exhaustion compounding the risk for developing cardiovascular diseases.
Previous studies have also shown that a decrease of circulating stem cells can
be an important determinant of age-related conditions 136. Injection of EPC into
the circulation of ischemic asythmic models shows a striking result, animals have
increased limb salvage and increased angiogenesis of the ischemic leg 137.
By studying how pollutants affect EPCs we may be able to understand
their mechanism of cardiovascular toxicity and to assess the cardiovascular
disease risk due to pollutant exposure.

Goals of the project
The overall thesis of the work presented here is that exposure to environmental
pollutants such as acrolein could deplete EPC levels or interfere with EPC
mobilization, and thereby increasing the risk of developing cardiovascular
disease and endothelial dysfunction. Although EPCs express high levels of
manganese superoxide dismutase (MnSOD) and therefore are likely to be
resistant to oxidative injury, recent studies have shown that exposure to
tobacco smoke or the cardiovascular disease decreases EPC levels.
Nevertheless, the mechanisms by which EPC levels are decreased under these
conditions remain completely unknown .. Hence, the aim of this project was to
examine how inhalation exposure to a ubiquitous environmental pollutant such as
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acrolein affects circulating EPC levels (Aim 1) and to understand the mechanism
by which acrolein inhalation affects EPC mobilization (Aim 2) . To assess the
functional significance of the effects of acrolein on EPCs, I also studied how
exposure to this aldehyde affects EPC mobilization after hind-limb (Aim 3). The
main purpose of these studies was to learn more about the mechanisms of
cardiovascular toxicity due to acrolein exposure.
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CHAPTER II:
ACROLEIN INHALATION DECREASES CIRCULATING LEVELS OF
ENDOTHELIAL PROGENITOR CELLS

Introduction
Several epidemiological studies show that exposure to combustion products
increases the risk of developing cardiovascular disease. In many large
population-based studies, long-term exposure to traffic-generated combustion
products has been found to be associated with an increased risk for coronary
heart disease 138, atherosclerosis 139 and fatal myocardial infarction 140. Likewise,
exposure to products of wood or coal combustion is linked to increases in blood
pressure and cardiovascular mortality 141,142. Moreover, individuals such as bus
drivers 143, chimney sweeps 144 and firefighters 145, who are repeatedly exposed to
combustion products, have significantly higher rates of cardiovascular mortality
than the general population. In addition, extensive data show that cardiovascular
disease and mortality are increased by exposure to combustion products
generated during smoking 146 or present in secondhand tobacco smoke 147.
Experimental data with humans or animals exposed to automobile exhaust 148 or
tobacco smoke 146,

147

support these epidemiologic findings. These studies

suggest that combustion products induce adverse cardiovascular effects.
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Nonetheless, the chemicals that mediate the cardiovascular toxicity of
combustion products are unidentified.
Combustion of organic material results in the generation of a complex
chemical mixture. The composition of this mixture varies with the source;
however, one of the chemicals common to all combustion sources is acrolein. It
is produced in high amounts during combustion of organic material in any form
(coal, wood, paper, cotton, gasoline, diesel or tobacco)149. Recent estimates
show that high levels of acrolein (between 6-8 ppm 150) are present in exhaust
gases from petrol and diesel engine vehicles, and tobacco smoke (100-600
1l9/cigarette)151 generates up to 50-70 ppm acrolein. Acrolein is a highly reactive
and toxic chemical,76, 152 which could account, at least in part, for the
cardiovascular toxicity induced by combustion products. Our previous studies
showed that acrolein inhalation leads to endothelial dysfunction in susceptible
mice 153. Endothelial injury is also an early and integral feature of the
cardiovascular toxicity of automobile eXhaust 148, tobacco 146,147 and wood
smoke 154 exposures. However, mechanisms by which these exposures affect
endothelial health remain unclear. Recent work suggests that endothelial repair
and regeneration depends, in part, upon circulating cells with pro-angiogenic
potential 86 . These cells with pro-angiogenic potential have been coined
Endothelial progenitor cells (EPCs) and are also known as Flk+/Sca+ cells, they
possess both endothelial markers and stem cell markers. The blood level of Flk-

1+ISca-1 + cells is a sensitive index of endothelial health and is inversely
correlated with cardiovascular disease risk 86 . This current study was, therefore,
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designed to test the hypothesis that acrolein exposure adversely affects the
number and mobilization of circulating Flk-1 +tSca-1 + cells.

Methods
Acrolein Exposure
Acrolein atmospheres were generated from liquid acrolein (Sigma-Aldrich, St.
Louis, MO, USA;

~90%;

diluted in dH 20, 1:10). Acrolein exposure was

performed using a custom vapor system (Teague Enterprises, Inc., Woodland,
CA, USA) with a primary chamber as a constant source, and acrolein vapors
diluted with HEPA-filtered room air in a secondary chamber. During exposure,
acrolein concentration was continuously monitored using an in-line photo
ionization detector (ppb RAE+, Rae Industries, Sunnyvale, CA, USA) upstream of
the cage insert vapor delivery unit (Teague Enterprises, Inc.) mounted on a
standard polycarbonate rat cage (41 cm x 34 cm x 21 cm; ==-31 L). Air or acrolein
was distributed through a fine mesh screen at 3 Ipm by delivery units with a
cyclone-type top that distribute air within 10% of the mean concentration at six
locations in the cage (Scheme 3). Exposure cages were placed partially over
heating pads (==-22 °C) to allow mice to select preferable temperature. Mice were
exposed to 5ppm acrolein for 2 or 6 h (5010±49ppb of 2 different exposures) or
to 1ppm acrolein for 4 days (1 ,053±22ppb of 5 different exposures)

(Scheme 4).
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Scheme 3: acrolein inhalation setup
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Circulating endothelial progenitor cell mobilization
Acrolein (1 ppm 6hr/4d) and Air (HEPA air 6hr/4d) exposed mice were injected
with saline of VEGF165 for 4 consecutive days. Immediately after the final
exposure, VEGF-injected mice received the CXCR4 antagonist, AMD3100, and
control mice received saline. Mice were the euthanized 1hr after AMD31 00 or
saline injection (Scheme 5).
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Scheme 5: VEGF/AMD3100 treatment regime
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Peripheral blood mononuclear cells and flow cytometry
Whole blood (300-400 IJI) was lysed (4 ml; BD PharmLyse, BD BioSciences, San
Jose, CA, USA; 10 min, RT) and after centrifugation (5 min, 400xg, RT), the
supernatant was aspirated and the lysing/centrifugation/aspiration steps were
repeated. The cell pellet was resuspended in 1% FBS/PBS and divided into 2
equal fractions. One fraction was fluorescently-Iabeled with anti-Sca-1 and antiFlk-1 antibodies tagged with FITC (Fluorescein Isothiocyanate) and APC
(Allophycocyanin), respectively. Following centrifugation (5 min, 400xg, RT),
mononuclear cells were re-suspended in 1% FBS/PBS (20 IJI) with murine
CD16/CD32 Fc Block to prevent non-specific binding to cell surface markers (0.5
IJg; BD Biosciences) and incubated for 10 min on ice. The FITC-Sca-1 (1 IJg; BD
BioSciences) and APC-Flk-1 (1 IJg, BD BioSciences) antibodies or appropriate
isotype controls(1 IJg; BD BioSciences) were added to cells (23 IJI) and incubated
for 30 min on ice. Cells were then washed with 1% FBS/PBS (400 IJI) and
centrifuged (5 min, 400xg, RT). Cells re-suspended in 1% FBS/PBS (400 IJI)
were analyzed using a LSRII flow cytometer (BD BioSciences). Based on
forward and side scatter, small non-debris events in a sub-lymphocyte population
(3-5 IJm; sized using fluorescent beads, BD Biosciences) were gated
electronically and displayed in a two-color dot plot. Data were subsequently
analyzed using FACSDiva v6.0 software (BD Biosciences), and double positive
events were normalized per 50,000 events or per IJI of assay volume.
Preliminary flow cytometry data indicated that ~98% of circulating Flk-1+/Sca-1+
cells were also CD45+ (1 IJg, PerCP-CD45; BD Biosciences).
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Endothelial progenitor cell characterization
For better characterization EPCs were mobilized. Mice were injected with saline
or VEGF 165 saline (100 I-Ig/kg/d; Peprotech, Inc., Rocky Hill, NJ, USA) (n=4,4)
daily for 4 consecutive days, on the 5th day received CXCR4 antagonist,
AMD3100, and control mice received saline (5mg/kg, Lp., 1001-11; Sigma-Aldrich)
(n=4,4). Mice were euthanized 1h after AMD31 00 or saline injection. Whole
blood (1mL) was lysed (9 ml; BD PharmLyse, BD BioSciences, San Jose, CA,
USA; 10 min, RT) and after centrifugation (5 min, 400xg, RT), the supernatant
was aspirated and the lysing/centrifugation/aspiration steps were repeated. After
washing cells were resuspended in 2% FBS/PBS with FcBlock for staining. All
staining antibodies were purchased from eBioscience (San Diego). The following
antibodies were used for analysis in three different groupings: Stem cell marker
panel 1: Anti-Mouse CD150 FITC, Anti-Mouse Ly-6A1E (Sca-1) PE, Anti-Mouse
CD115 (c-fms) PerCP-eFluor® 710, Anti-Mouse CD48 PE-Cy7, Anti-Mouse
CD309 (FLK1) APC, Anti-Mouse CD11 b APC-eFluor® 780, Anti-Mouse CD34
eFluor® 450, Anti-Mouse CD38 Biotin-Streptavidin 605 nanocrystal; Stem cell

marker panel 2: Anti-Mouse CD133 (Prominin-1) Biotin 605, Anti-Mouse CD150
FITC, Anti-Mouse Ly-6A1E (Sca-1) PE, Anti-Mouse CD115 (c-fms) PerCPeFluor® 710, Anti-Mouse CD48 PE-Cy7, Anti-Mouse CD309 (FLK1) APC, AntiMouse CD11 b APC-eFluor® 780, Anti-Mouse CD34 eFluor® 450; T and 8-cell

marker panel 3: Anti-Mouse CD8a PerCP-Cy5.5, Anti-Mouse CD3 APC-eFluor®
780, Anti-Human/Mouse CD45R (B220) eFluor® 450, Anti-Mouse CD4 eFluor®
605NC, Anti-Mouse CD31 (PECAM-1) FITC, Anti-Mouse Ly-6A1E (Sca-1) PE,
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Anti-Mouse C0309 (FLK1) APC, and Anti-Mouse C019 PE-Cy7. Cells were
analyzed by flow cytometry (BO LSRII, BioSciences) and data were analyzed
using FlowJo (TreeStar Software; Ashland Oregon).

Isolation and culture of bone marrow-derived cells (BMDCs)
Bone marrow was aspirated from femur and tibia of both legs with 1mL HBSS
(Clonetics/Lonza, Walkersville, MO, USA), and mononuclear cells were
separated by Ficoll gradient centrifugation (Ficoll-Paque PREMIUM, GE
Healthcare, Piscataway, NJ, USA; 400xg, 20 min, 4°C). Trypan blue-viable cells
(2-4x1 06 cells per mouse) were isolated and 8x10 5 cells were seeded on
fibronectin-coated, 8-well chamber slides (10% human fibronectin, SigmaAldrich) in 500 IJL endothelial basal media (Clonetics/Lonza) supplemented with
20% FBS (Invitrogen, Carlsbad, CA, USA), human endothelial growth factor
(hEGF), hydrocortisone, gentamycin/amphotericin B (GA) and bovine brain
extract (BBE)(SingleQuot®, Clonetics/Lonza) under standard cell culture
conditions (3rC, 5% CO 2 )155. On day 7, cells were incubated with Oil-acLOL
(2.4 IJg/mL, Invitrogen) in media for 3 h. After media was removed, cells were
washed three times with PBS, fixed in 4 % PFAlPBS (pH 7.4; RT) for 10 min, and
then incubated with FITC-UE-Iectin (50 IJgI mL, Sigma-Aldrich) at 3rC for 30
min. For labeling of Flk-1 and Sca-1, cells were incubated with FITC-Sca-1 (1 :25;
BO BioSciences) and APC-Flk-1 (1 :15, BO BioSciences) antibodies for 1 h at RT.
Cells were washed three times with PBS before slides were stained with OAPI-
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containing Slow Fade® Gold anti-fade reagent (Invitrogen). DiI-acLDL and FITCUE-Iectin double-positive cells were counted in 10 random fields.

Blood counts and plasma biochemistry
After select exposures, 100 1-11 of blood were used for complete blood count
analysis (CBC; Hemavet 500, Coulter Counter, Oxford, CT). Plasma total, HDL
and LDL cholesterol, triglycerides, total protein, albumin (Cholesterol CII
Enzymatic Kit; L-Type TG-H Kit; Bradford reagent, bromocresol green, Wako,
Richmond, VA, USA), AL T, AST (Infinity, ThermoElectron, Louisville, CO, USA),
CK and LDH (Promega, Madison, WI, USA) levels were measured using
commercially available assay reagents as indicated. Assays were performed
using calibrated standards in 96-well plates or using a Cobas Mira Plus 5600
Autoanalyzer (Roche, Indianapolis, IN, USA). Plasma NO x level (stable NO
metabolites, nitrate and nitrite; 25 1-11) was measured fluorimetrically according to
manufacturer's instructions (NO x kit; Calbiochem, Darmstadt, Germany).

Isolated aorta studies
Thoracic aorta were isolated and tested for intact VEGF signaling. Isolated aortas
were incubated in autologous plasma and exposed to VEGF 165 for 15 min before
freezing.
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Vascular reactivity
Thoracic aortas were isolated and vascular reactivity was assayed as described
previously

11.

Briefly, one 3-4-mm ring per mouse was hung on stainless steel

hooks in 15-ml water-jacketed organ baths in physiological salt solution (PSS)
bubbled with 95% O2 and 5% CO 2 at 3rC. The composition of PSS was (in
mM): NaCI, 130; KCI, 4.7; MgS04·7H20, 1.17; KH2P04, 1.18; NaHC0 3 , 14.9;
CaCI2, 2.0; glucose, 5.0; pH 7.4. Rings (::=1 g loading tension) were contracted
with 100 mM potassium solution (2 times) followed by cumulative concentrations
of phenylephrine (PE; 0.1 nM - 10 IJM). PE-precontracted rings were relaxed
with cumulative concentrations of acetylcholine (ACh; 0.1 nM - 10 IJM) or of
sodium nitroprusside (SNP; 0.1 nM -10 IJM) to measure endothelium-dependent
or -independent relaxation, respectively. Vessel contraction was quantified as
mg tension, active stress (in mN/mm2) or normalized as percentage of the
maximum PE contraction. Relaxation was calculated as percentage reduction of
PE-induced tension. The effective concentration producing 50% response (EC 50 )
was assessed by normalizing cumulative concentration responses to 100%,
plotting the response vs. the log [molar]

agonist,

and then interpolating the EC50

value.

Western blot analyses
Bone marrow aspirates were centrifuged and pellets were suspended in lysis
buffer (25 mM HEPES, pH 7.0; 1 mM EOTA; 1 mM EGTA; 1% Nonidet P40; 1%
SOS) supplemented with 1:100 protease inhibitor cocktail (Sigma-Aldrich), 1:100
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phosphatase inhibitor cocktail and 50mM N-ethylmaleimide (NEM; Pierce,
Rockford, IL, USA). After sonication, samples were centrifuged (4,OOOxg, 15
min, 4°C) and supernatants were used for detection of protein-acrolein adducts
by Western blotting. Pulverized aortas were lysed in RIPA buffer (50mM
Tris-HCI, pH 7.4, 150mM NaCl, 1mM EOTA, 0.25% sodium desoxycholate, 1%
NP-40; 1: 100 protease inhibitor cocktail; 1: 100 phosphatase inhibitor), sonicated
and centrifuged (13,OOOxg, 15 min, 4°C). Heart was homogenized in membrane
preparation lysis buffer (25mM Tris; 0.5mM EOTA; 0.5mM EGTA; protease
inhibitor 1:100 dilution; phosphatase inhibitor, 1:100; pH 7.5) and centrifuged

(14,OOOxg, 15 min, 4°C). Pellet was resuspended in lysis buffer supplemented
with 1% NP-40 and incubated for 4h

156.

After incubation and second

centrifugation, the supernatant was collected as membrane fraction. Lungs were
homogenized in ice cold lysis buffer (50mM Tris-HCL; 1mM EOTA; 1mM EGTA;
protease inhibitor, 1:100; phosphatase inhibitor, 1:100 dilution; pH 7.4). Lysates
were centrifuged (14,OOOxg, 15 min, 4°C) and supernatants used for Western
blotting

157.

Total protein was measured using a commercially available kit (Bradford, BioRad, Hercules, CA, USA). For Western blot analysis of protein-acrolein adducts,
protein samples (150 I-Ig) in 5x sample buffer (312.5 mM Tris base, pH 6.8 [BioRad] or, 10% Glycerol, 11.5% SOS, 0.1 % Bromphenol) supplemented with 50
mM NEM were separated under non-reducing conditions, whereas all other
proteins (30-100 I-Ig) were separated under reducing conditions (buffer
supplemented with 50 mM OTT). Briefly, heat-denatured (5 min, 95°C) protein
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samples were separated by SDS-PAGE and transferred to PVDF membranes
(Bio-Rad). Membranes were processed by standard immunodetection
techniques using a rabbit polyclonal antibody against KlH (Keyhole Limpet
hemocyanin)-protein-acrolein adduct

158

or using a commercially available

antibody against Phospho-Akt (Ser473), Akt, Phospho-eNOS (Ser1177), eNOS
(BD Biosciences, 1: 1000), Phospho-p42/44 (Thr202ITyr204), p42/44 (1: 1000;
Cell Signaling) or VEGFR-2 (1 :2S0; Santa Cruz) or MMP-9 (1 :SOOO, Chemicon,
Millipore, Temecula, CA, USA). Western blots were developed using ECl® plus
reagent (Amersham Biosciences, Piscataway, NJ, USA) and detected with a
Typhoon 9400 variable mode imager (Amersham Biosciences). Actin antibody
(1 :2000, Sigma-Aldrich) detection or amido-black staining was used as loading
control. Quantification of band intensities was performed using Image Quant Tl
software (Amersham Biosciences).

Histology and immunohistochemistry
Pelvic bones were formalin-fixed (10 % neutral buffered formalin) for 24h,
decalcified in Immunocal® (Decal Chemical Corp., Tallman, NY) for 6h, and
washed in running tap water (O.Sh). Paraffin-embedded sections (S IJm) of pelvic
bones were stained with hematoxylin/eosin, anti-protein-acrolein adduct (rabbit
polyclonal; 1:1 ,OOO), or normal rabbit or goat IgG (as negative controls) 158. A
goat anti-rabbit secondary antibody and a Vector Elite staining kit with
diaminobenzadine (Dako) as chromagen were used.
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MoFlow cell sorting and 101 staining
Whole blood (1000 1-11) was lysed (10 ml; BD PharmLyse, BD BioSciences, San
Jose, CA, USA; 10 min, RT) and after centrifugation (5 min, 400xg, RT), the
supernatant was aspirated and the lysing/centrifugation/aspiration steps were
repeated. The cell pellet was resuspended in 1 % FBS/PBS and divided into 2
equal fractions (i.e., isotype control or Flk-1/Sca-1 labeling). After centrifugation
(5 min, 400xg, RT), mononuclear cells were re-suspended in 1% FBS/PBS with
murine CD16/CD32 Fc Block (0.5 I-Ig; BD Biosciences), incubated for 10 min on
ice, followed by 30 min incubation on ice with anti-Sca-1 (FITC, 1 I-Ig; BD
BioSciences) and anti-Flk-1 (1 I-Ig, BD BioSciences) antibodies or appropriate
isotype control (1 I-Ig; BD BioSciences). Cells were then washed with 1%
FBS/PBS and centrifuged (5 min, 400xg, RT). Based on forward and side scatter,
small non-debris events were gated electronically and 200 labeled Flk-1 +/Sca-1 +
cells were sorted into a 1.7 uL centrifuge tube containing 2 % FBS/PBS using
MoFlo® (Beckman-Coulter). Cells were fixed with 1 % paraformaldehyde for 5
min. on ice. Triton-100X was then added to increase the permeability for 5 min.
on ice. Cells were then washed using 0.1 % Triton-1 OOX wash buffer, spun down
at 3rpm for 5 min. then aspirated. Cells were then stained with murine anti-ID1
(1 :50; Santa Cruze) for 30 min. in 0.1 % Triton on ice, then washed with 0.1 %
Triton wash buffer and aspirated. Cells were stained using secondary anti-rabbit
PE fluorophore (1 :25;). Cells were once again washed with 2 % PBS/FBS spun
down and aspirated. Then 100uL of 2 % FBS/PBS was added and then cell spun
onto a cytospin slide at 300Xg. Slides mounted in DAPI-containing Slow Fade®

49

Gold anti-fade reagent (Invitrogen), and viewed using a Zeiss confocal
microscope.

Results
Flk+/Sca+ Cell characterization
To better understand the selective nature of acrolein inhibition, a more extensive
screen of antigenic markers on Flk-1+/Sca-1+ cells (stem/progenitor and B-/T-cell
markers) from saline and VEGF/AMD3100-treated mice was conducted by flow
cytometry. VEGF/AMD3100 significantly increased Flk-1 +JSca-1 + cells
expressing a variety of stem and B-/T -cell antigenic markers especially cells coexpressing CD31/CD45R(B220)JCD133 and CD31/CD45R(B220)/CD19 (Fig.
2A-F).

Effects of acrolein on circulating Flk-1+/ Sca-1+ cells
Analysis of the mononuclear cell population of peripheral blood showed that Flk1+/Sca-1 + cells were a relatively small (3-5 j.Jm), sub-lymphocytic, non-debris cell
population with further characterization showing stem and endothelial cell
markers (Figs. 3A-2E).
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Figure 2: Hierarchical relationships of Flk+/Sca+ Cells.: A-B, Progenitor cell
antigens, and, C-D, lymphocytic differentiation marker antigens expressed on
Flk-1/Sca-1 cells. ,E, Progenitor cell antigens, and, F, lymphocytic differentiation
marker antigens expressed on Flk-1/Sca-1 cells.
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Figure 3
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Figure 3: Characterization of Flk-1 +/Sca-1 + progenitor cells by flow
cytometry and microscopy. Representative dot plots of A, forward(FSC) and side-scatter (SSC) of circulating cells and size beads indicating
an approximate size range of Flk-1+/Sca-1+ cells (3-5IJm) Dot plots of
SSC and PerCP-CD45 fluorescence of Flk-1 +/Sca-1 + cells representing
CD45 positive (CD45+, 98.5±O.3 %) and CD45 negative cells (CD45-,
1.2±O.3 %). Dot plots of FSC and PE-CXCR4 fluorescence of Flk-1 +/Sca1+ cells that are CXCR4 positive (97.2%).

B, Brightfield and confocal

images of Flk-1/Sca-1-double positive cells sorted by MoFlo for
immunofluorescence detection of antigen co-localization. C, Confocal
image of sorted Flk-1+/Sca-1+ cells stained with Id1 antibody. Nuclei were
stained with DAPI.
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Acrolein exposure induced a selective and dose-dependent decrease of
circulating Flk-1+/Sca-1+ cells (Fig. 4C). The number of Flk-1+/Sca-1+ cells was
significantly reduced by 77±10 % following exposure to 1 ppm acrolein for 4
consecutive days (6h/d; air: 413±109 cells per SO,OOO events; acrolein: 97±19
cells per SO,OOO events; n=8, 8; p<O.OS). However, acrolein exposures (1ppm;
6h/d) for 1,2, or 4 days did not affect the number of circulating Sca-1+ cells (Fig.
40). Exposure of mice to a higher dose of acrolein (S ppm; 6h), though,
decreased Flk-1+/Sca-1+ cells significantly by 43±10 % compared to air-exposed
mice (air: 4.3±0.7 cells/ IJL; acrolein: 2.4±0.4 cells/ IJL, n=8, 8; p<O.OS; Fig. 4E).
A brief acrolein exposure (Sppm; 2h), however, did not alter circulating Flk1+/Sca-1 + cells (air: 6.3±2.4 cells/ IJL; acrolein: 7. 7±1.4 cells/ IJL, n=4, 4; p<O.OS)
or Sca-1+ cell level. Acrolein exposure of O.S ppm (6h/d x 4d) had no effect on
the number of circulating Flk-1 +/Sca-1 + or Sca-1 + cells as compared with air
controls indicating a narrow threshold range of acrolein action. Furthermore,
mice allowed 7 days of recovery after a 4-day acrolein (1 ppm, 6h/d) exposure
had similar numbers of circulating Flk-1+/Sca-1+ cells compared with air-exposed
controls (Fig. 4E). Although 1 ppm acrolein (6h/d x 4d) did not alter plasma lipids
(Table 7) or leukocyte blood cell counts, a 6h exposure to a higher acrolein level
(S ppm) significantly decreased leukocyte blood cell counts (Table 8). Acrolein
exposure increased Annexin V/7AAD staining in circulating Flk-1/Sca-1 double
positive cells (Fig. 4G).
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Figure 4
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wi

Figure 3: Effects of acrolein on circulating progenitor cells. A, Flow
cytometry analysis of forward- (FSC) and side-scatter (SSC) of peripheral
blood mononuclear cells of mice breathing filtered air or acrolein (1ppm,
6h/day, 4 days). B, Representative two color (APC-Flk-1 and FITC-Sca-1)
flow cytometry dot plots of circulating Flk-1 +/Sca-1 + cells in peripheral
blood of mice after 4 days of exposure to filtered air or acrolein. Levels of
C, Flk-1+/Sca-1+ cells and 0, Sca-1+ cells in peripheral blood after
breathing filtered air or acrolein for indicated days (n=8-12). E, Flk-1+/Sca1+ cells in blood obtained from mice breathing filtered air or 5 ppm acrolein
for 2 or 6h. F, Flk-1+/Sca-1+ cells in blood of mice breathing air or 1 ppm
acrolein (6h/d, 4d) and after 7 days recovery G, Representative dot plots
of APC-Flk-1 and FITC-Sca-1 double positive cells stained for 7-AAD
(necrosis marker) and Annexin V (apoptosis marker), and quantification of
percentage Annexin V and 7-AAD stained cells from air and acroleinexposed mice. (n=4; * p<O.05).

64

Table 7
Blood and plasma variables in mice exposed to air or acrolein.
Air

Acrolein, 1ppm

Cholesterota

73.2:t3.1

70.1%2.7

60.9%4.1

52.2:1::0.3

HOL'

54.6:t3.2

45.6:*:3.6

45.8:*:3.2

50.2:1::0.3

LOLa

10.3:1::0.2

10.9:1::0.7

8.1 :1::0.6

9.4:1::0.2

Triglycerides l

17.9:*:3.1

14.5:*:1.9

24.8%4.7

17.7:1::0.3

TPb

4.1:1::0.1

3.8:1::0.1

3.7:1::0.1

3.7:1::0.8

ALBb

2.7:1::0.1

2.7:1::0.1

2.5:1::0.1

2.5:1::0.9

LOHC

167.6:*:17.2

127.2:*:9.9

264.5%26.1

167.5:*:12.1·

CKe

261.6%21.2

245.1:*:30.1

198:t8.2

247:t5.3

ALT'

56.5:*:7.8

48.2:i:6.4

25.7:*:3.6

25.8:1::0.9

ASTc

42.2*7.3

~5.9*3.9

62.8:t8.7

69.3:*:10.7

Air

Acrolein.5ppm

Male, 12-14 week old mice were exposed to air or 1 ppm acrolein (6h1d, 4d. n=11
mice/group) or 5 ppm acrolein (6h1d. 1d. n=4 mice/group). Values are mean:*: SEM.
Abbr: HOL. high density lipoprotein cholesterol: LOL, low density lipoprotein cholesterol;
TP, total protein; ALB. albumin; LOH. lactate dehydrogenase; CK, creatine kinase: ALT,
alanine aminotransferase; AST, aspartate aminotransferase. Units: I = [mg/dL]. b =
[g/dL). C [UIL]; ., p<O.05 VI. Air-matched group.

=
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Table 8
Complete blood count in mice exposed to air or acrolein.

waC·

Air
2370:t585

NE~

Acrolein.1ppm

Air

Acrolein, 5 ppm

1775~93

2690~81

93~3·

362%64

355:t51

472%61

138*16·

LYI

1942:t518

1448~62

213~25

752~1·

Mea

57*15

60*10

78*15

35:t5*

RBCb

9.03~.30

8,92~.24

8.18~.27

8.24~.26

HCt (%)

42.2*1.2

41.4*1.3

37.4*1.1

36.9*1.2

Hbc

11.1~.3

11.1~.3

11.3~.1

12.2~.2

MCVd

46.9~.3

46.3~.6

45.7~.3

44.8~.4

MCH'

12.2~.1

12.4~.2

14.3~.1

14.4~.2

MCHCc

26.1~.1

31.2~.3

32.1~.3

ROW(%)

17.3~.5

17.5*1.7

17.3~.3

16.7~.1

PLTI

835:t50

789~6

845~7

758~8

MPVd

3.8~.1

3.8~.1

4.1~.1

3.9~.2

26.8~.5

Male, 12-14 week old mice were exposed to air or 1 ppm acrolein (6h1d. 4d. n=8
mice/group) or 5 ppm acrolein (6hld. 1d, n=4 mice/group). Values are mean * SEM.
Abbr. WBC. white blood cells; NE. neulrophils: LY.lymphocytes: MO, monocytes; RBC.
red blood cells; HCt. hematocrit; Hb. hemoglobin; MCV, mean corpuscular volume;
MCH. mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration; ROW, red cell distribution width; PLT. platelets; MPV. mean platelet
volume. Units: a [x10 1/fJL). b [x106/fJL), C (g/dL). d [fL). • [pg]; *, p<0.05 VI. airmatched group.

=

=

=
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Acrolein exposure increased number of bone marrow-derived cells (8MOC)
To further evaluate the condition of the EPC within the bone marrow culture was
performed. Acrolein exposure increased the number of Dil-acLDLlFITC-UElectin-double positive cells in culture on day 7 (Fig. 5). After 7 days of culture,
outgrowths from bone marrow-derived DiI-acLDLlFITC-UE-lectin-double positive
cells (Fig. 58), had more cells from acrolein-exposed mice than air-exposed as
indicated by DAPI staining (nuclear; blue fluorescence; Fig. 58). Furthermore,
the cells positive for Dil-acLDL (red fluorescence) and FITC-UE-Iectin (green
fluorescence) were increased by acrolein exposure compared with air-exposed
controls (Fig. 58). Image overlay showed co-localization of EPCs markers (DilacLDL, FITC-UE-Iectin) indicating that acrolein enhanced the proliferative
capacity of endothelial progenitor-like cells (orange) in culture. Compared with
cells from air-exposed (control) mice, there was a 3- to 3.6-fold increase in the
Dil-acLDLlITC-UE-lectin double positive cells isolated from mice exposed to
acrolein (5 ppm, 6h; Fig. 5C; 1 ppm, 4d; Fig. 50) after 7 days in culture. The
identification of these proliferating cells as endothelial progenitor-like cells was
also supported by immunocytochemical staining of cultured BMDC for APC-Flk-1
and FITC-Sca-1 (i.e., markers used in flow cytometry) on culture day 7. Thus, in
comparison with air, acrolein exposure (1 ppm, 4d) increased Flk-1+t Sca-1+ cells
by 1.7-fold. Taken together, these data showed that acrolein exposure enhanced
bone marrow-derived endothelial progenitor-like cell proliferation in culture.
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Figure 5
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Figure 5: Acrolein increases proliferation of bone marrow-derived cells.
Representative fluorescence images (upper panels) and the number of
(lower panels) of Dil-acLDL+/FITC-UE-lectin+ cells isolated from bone
marrow of mice exposed to air or B, 5 ppm acrolein for 6h C, or 1 ppm
acrolein (6h/d, 4 days). Mononuclear cells were isolated from the bone
marrow and grown in culture for 7 days. Cells were labeled with DiI-acLDL
and FITC-UE-Iectin and nuclei were stained with DAPI. Merged images
show co-localization of both markers in orange (i.e., double-positive cells).
D, Representative fluorescence images (upper panel) and analysis (lower
panel) of Flk-1+/Sca-1+-cells from mice exposed to air or 1 ppm acrolein
(6h/d, 4d) after day 7 of culture. Cells were labeled with FITC-Flk-1 and
APC-Sca-1 and with DAPI for nuclear staining. Merged images show colocalization of the markers. Changes in the number of Dil-acLDL +/FITCUE-Iectin+ and Flk-1 +/Sca-1 +cells are presented as fold increase in double
positive cells compared with controls (n=4; * p<O.05, air vs. acrolein
exposure).
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Protein acrolein adducts
To determine whether acrolein could directly reach the bone marrow cells, we
examined the abundance of protein-acrolein adducts in plasma and bone marrow
by Western blotting and immunohistochemistry (Fig. 6). Protein-acrolein adducts
were detected by Western blotting of plasma (Fig. 6A) and bone marrow Iysates

(Fig. 78) of air- and acrolein-exposed (1 ppm, 4d) mice. Abundant acrolein
adducts were observed in proteins with molecular weights of ==250 and ==150 kOa
in plasma and of ==250, ==37, ==18 and ==17 kOa in the bone marrow. Acrolein
inhalation led to a significant increase in the intensity of several bands, including
a 2.5-fold increase in a plasma protein band of ==150 kOa and a 2-fold increase
for a bone marrow protein band of ==250 kOa, compared with controls (Fig. 6).
Similarly, immunohistochemical staining of femur (proximal head) cross-sections
with protein-acrolein adduct antibody was substantially stronger in acroleintreated (1 ppm, 4d) bone compared with controls (Fig. 6C). Adduct distribution
was quite heterogeneous in both acrolein- and air-exposed mice, however,
distinct, intense positive staining of protein-acrolein adducts was observed in
blood vessels within the connective tissue as well as in the ostea of the bone
trabeculae (Fig. 6C, see black arrows). More diffuse staining was present in the
bone marrow matrix, i.e., hematopoietic tissue (Fig. 6C, yellow arrows), where
some focal, intense staining was localized to the largest bone marrow cells within
the endosteum at the border between the bone marrow cavity and compact bone

(Fig. 6C, yellow arrow).
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Figure 6
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Figure 6: Formation of protein-acrolein adducts. Western blot analyses of
protein-acrolein adducts in A, plasma or B, bone marrow extracts obtained from
mice breathing air or 1 ppm acrolein for 4 days (6h/d). Amido-black stain
(plasma) and actin detection (bone marrow) were used as loading controls. C,
Bone marrow immunohistochemistry of acrolein antibody staining, air v. acrolein
inhalation. Data are presented as fold increase of protein-acrolein adducts after
acrolein exposure compared with air-exposed mice (* p<O.05; n=4-5).
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Endothelial dysfunction and NO signaling
The number of circulating Flk-1 +/Sca-1 + cells is in continuous flux due to the
competing processes of mobilization (e.g., bone marrow/spleen) and recruitment
to sites of injury (e.g., endothelium). To determine if the acrolein-induced
decrease in circulating Flk-1+/Sca-1+ cells was due to increased recruitment to
vascular sites of injury, endothelium function was measured in isolated aorta
following exposures. No evidence of frank vascular smooth muscle or
endothelial cell dysfunction was found after 1 ppm acrolein exposure (6h/d x 4d;
Table 9), which is consistent with a previously published study using 1 ppm
acrolein exposure in C57BLl6 mice

153.

In contrast, brief exposure of mice to 5

ppm acrolein (6h) induced a modest, yet significant, rightward shift in the
acetylcholine-mediated vasorelaxation in phenylephrine-precontracted aorta
indicating endothelial dysfunction (Fig. 7A; Table 9). There was no change in
total percentage of NO-donor-mediated (sodium nitroprusside, SNP) relaxation,
although there was a significant leftward shift in aortic sensitivity to SNP (EC 50 :
air, 16±3 nM; acrolein, 9±1 nM, n=8, 8, p<O.05; Table 9) - further indicating an
endothelium-specific dysfunction.
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Table 9
Vascular effects of air or acrolein exposure in mice.
Air

Acrolein, 1ppm

Air

Acrolein,S eem

PhenxleRhrin! (pel
Tension(mg)

738~74

659z62

1037~156

723:t83

Active Stress (mN/mm2)

8.9~.9

8.1~1.2

na

na

EC50{nM)

149~15

149~15

151~33

160~6

p02

6.84~.05

6.84~.05

6.88~.09

6.83~.07

Relaxation (% PE)

-63~

-64~7

-66:t8

-66~

EC50(nM)

136~1

195:t82

113~0

180~4·

p02

6.92~.09

6.92~.15

7.00~.10

6.77~.06t

Ace~lcholine (ACh)

Sogium NitroRrusside ,§NP)
Relaxation (% PE)

-121~

·121z6

-103~

·104~

EC50(nM)

15~3

18~3

16~3

9~1·

RQ2

7.~1~.1Q

7.§Q~.Q7

7.§4~.09

§.08~.Q§·

Male. 12-14 week old C57BU6mice were exposed to air or acrolein (1 ppm, 6h1d. 4d or
5ppm, 6h/d, 1d). Values are mean ~ SEM. Abbr: HI K+, 100 mM potassium buffer; na,
not available; EC50 == effective concentration producing 50% response; p02, Q(EC50);;
• P!O .05 VS. matched air control (n=7..a mice/group); 1 0.1 0>p>0.05 VI. matched"'r
control.
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To examine whether acrolein-induced endothelial dysfunction was due to
changes in nitric oxide (NO) bioavailability, we examined changes in plasma of
the stable end products (nitrate and nitrite) of the I-arginine/nitric oxide
biosynthetic pathway otherwise known as NOx, total eNOS, and the
phosphorylation status of eNOS and Akt, which are critical mediators of
endothelial signaling and function (Fig. 8). Acrolein exposure at 1 ppm (6h/d x
4d) or 5ppm (6h) significantly decreased plasma NO x levels by 15 % (air: 100±8
%; acrolein: 85±4 %; n=8, 8; p<O.05) or 22 % (air: 100±8 %, acrolein; 78±4 %,

n=8, 8; p<O.05), respectively (Fig. 7C). The acrolein-induced suppression of
plasma NO x level after 4-day acrolein exposure was reversed by 7 days of
recovery in acrolein-free air (Fig. 7A). Similarly, the recovery of plasma NO x
level coincided with a return of circulating Flk-1+/Sca-1+ cell numbers in acroleinexposed mice to the air control level (Fig. 4F).
Because acrolein exposure decreased both plasma NO x and Flk-1+/Sca-1+
cell levels, eNOS protein content was measured in Iysates of lung, heart and
aorta (Fig. 7C) by Western blotting. Additionally, VEGFR-2 abundance was
measured by Western blotting in bone marrow Iysates. As shown in Figure 7C,
acrolein exposure (1 ppm; 6h/d x 4d) did not alter eNOS protein abundance in
lung, heart or aorta, nor did it change VEGFR-2 protein level in the bone marrow.
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Figure 7
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Figure 7: Endothelial response to acrolein exposure. A, Endothelial function
assay from aorta of mice exposed to Sppm 6hr acrolein (n=4, * p<O.OS) B,
NO x levels in plasma of mice breathing filtered air or acrolein (n=8, *

p<O.OS). C, Western blot analyses of eNOS or VEGFR2 in Iysates of lung,
heart, aorta or bone marrow of mice breathing filtered air or 1 ppm
acrolein (6h/d, 4d). Group densitometry data are presented as mean ±
SEM (n=4). * p<O.OS.
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Air
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Figure 8: Effects of acrolein on enzymatically important constituents of
EPC mobilization. A, Representative Western blots of phospho-eNOS
(Ser1177). phospho-Akt (Ser473). eNOS and Akt in Iysates of aortas obtained
from animals exposed to air or Acrolein (5 ppm/6h) B. Akt and C. MMP-9 in
Iysates of bone marrow obtained from animals exposed to air or acrolein (5
ppm/6h). Group data are presented as mean ± SEM. n=4.
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VEGF+AMD3100-induced mobilization of Flk-1+/Sca-1+ cells
Because acrolein exposure decreased circulating Flk-1 +/Sca-1 + cells in the
absence of frank aortic endothelial dysfunction, we tested if acrolein perturbed
progenitor cell mobilization. Acrolein alone (1 ppm, 4d) significantly decreased
Flk-1 +/ Sca-1 + cells compared with air controls (air + saline: 1.5±0.3 cells/ IJL;
acrolein + saline: 0.7±0.1 cells/ IJL; n=4, 4; p<0.05; Fig. 9A). As shown before,
VEGF+AMD3100 treatment led to a 3-fold increase in circulating Flk-1+/Sca-1+
cells

159.

Acrolein inhalation significantly and specifically impeded

VEGF+AMD3100-induced Flk-1+/Sca-1+ mobilization (normalized to air control:
air+VEGF+AMD31 00: 3.0±0.4 cells/ IJL; acrolein+VEGF+AMD31 00: 0.4±0.1
cells/ IJL, n=8, 8; p<0.05; Fig. 9A). Although VEGF+AMD3100 treatment
significantly increased Sca-1 + cells (normalized to air control:
air+VEGF+AMD31 00: 2.8±0.4 cells/ IJL; acrolein+VEGF+AMD31 00: 2.9±0.4
cells/ IJL, n=8, 8) and overall white blood cell counts, indicating general
mobilization of both stem cells and leukocytes, these effects were unaltered by
acrolein exposure (Table 10), indicating that acrolein specifically decreased the
endothelial progenitor cell population.
Co-treatment with VEGF+AMD31 00 is known to modify mobilization without
changing bone marrow cell function

159.

Treatment with VEGF+AMD31 00 did not

alter aortic eNOS or Akt protein levels as analyzed by Western blotting
regardless of exposure (Fig. 98-C).
Our results indicate that acrolein at 1 ppm inhibits mobilization of Flk-1 +/Sca1+ cells via diminished NO bioavailability and impaired VEGF/ CXCR4 signaling.

85

Henceforth, we studied VEGF signaling in aortas isolated from air- or acrolein- (1
ppm, 6h/d x 4d) exposed mice. Aortas were incubated ex vivo with VEGF (20 ng/
mL) for 15 min and phosphorylation status of Akt (Fig. 90), eNOS (Fig. 9E) and
ERK (Fig. 9F) proteins was analyzed. In control aortas, VEGF stimulated
phosphorylation of Akt (2-fold) and eNOS (2-fold) - an effect absent in aortas of
acrolein-exposed mice (Figs. 90 and 9E). Although VEGF-induced
phosphorylation of ERK was not influenced by inhalation exposure, acroleinexposed aortas had a significantly greater level of basal phospho-ERK (p42/44)
(Fig. 9F). These findings indicated that acrolein exposure significantly impaired
VEGF/ CXCR4 signaling - an effect that could account for the diminished levels
of basal and VEGF+AMD3100-mobilized Flk-1+/ Sca-1+ progenitor cells, as well
as, the decreased plasma NO x level
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Figure 9
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Figure 9: Effect of acrolein on the mobilization of Flk-1 +/Sca-1 + cells. A,
Representative two color (Flk-1 and Sca-1) flow cytometry dot plots (upper
panel) of circulating cells in the peripheral blood of mice breathing filtered
air or 1 ppm acrolein (6h/d, 4 d) after combination of VEGF/AMD3100
treatment. Levels of Flk-1 +ISca-1 + cells per IJI blood (left y-axis) and Sca1+ cells (right y-axis; fold-change relative to air control) of mice breathing
filtered air or 1 ppm acrolein (6h/d, 4d) after treatment with
VEGF/AMD3100 (* p<O.05, n=8). B, Representative Western blots and
densitometric analysis of Akt in bone marrow Iysates obtained from mice
after saline or VEGF/AMD3100 treatment (n=4). C, Representative
Western blots and densitometric analysis of eNOS in Iysates of aortas
obtained from mice breathing air or acrolein (1 ppm, 6h/d, 4d) after saline
or VEGF+AMD3100 treatment (n=4). O-F, Analysis ofVEGF signaling in
aortas isolated from mice breathing air or acrolein (1 ppm, 6h/d, 4d) and
treated with VEGF in autologous plasma for 15 min. Representative
Western blots and analysis of membranes probed for 0, phospho-Akt

(Ser473)/total Akt; E, phospho-eNOS (Ser1177)/total eNOS; and F,
phospho-ERK (Thr202/Tyr204) Itotal ERK (n=3-7; * p<O.05).

90

Table 10

Compiete blood counts In mice exposed to air or acrolein

+81111 ....

Au

+VEGF+AMD3100

Acrolein, 1ppm

AJr

Acrolein, 1ppm

wac'

1365+..210

2131:!:368'

763Ot:81 0'

8030±475t

NEt

422±79

497:t179'

2345!362'

2821!280 f

LY·

897±165

1600!192'

5042±494'

4981:1:2851

MO'

35±11

61±32'

232:!:1T

22O!161

RBO

6 72:tO 80

868:tO.33

7.94:tO 46

8 32:tO 47

HCt (%)

32 2:1:2 3

39 2.t1 5

34.~19

371:1:2 2

Hb'

9 1:t1 2

119:t06

108:tO 7

111:t05

MCV"

447:t07

451:tO 2

44 5:tO 3

442:t04

MCHe

13 3:t0 3

136:tO 1

134:tO 2

135:t03

MCHO

29.~05

305:tO 3

3O.8:tO 9

302:tO.5

RDW(%)

165:tO 3

17 3:tO 2

178:tO.2

17 3:tO 3

PlP

799!122

858:t76

917±'91

809±78

MPV"

4 4:tO 1

42:t0 1

44:tO 1

42:tO.1

Made, 12-14 week old mice were exposed to air or 1 ppm acrolein (6hld. 4<1, n=8
miCe/group) Values are mean t SEM Abbr wac, white blood cells. NE. neutrophlls,
LY, lymphocytes, MO. monocytes. RBC. red blood cells, HCt. hematocnt. Hb,
hemoglobtn, MCV, mean corpuscular volume, MCH, mean corpuscular hemoglobtn,
MCHC, mean corpuscular hemoglobtn concentration. ROW. red cell distnbubon WIdth,
PlT,platelets. MPV, mean platelet volume Urnts I:; [x1()3/J.1L), 0 : (x1()6/J.1l1, c: (g/dl],
= [fll, • (pg) *, p<O 05 vs air-matched group, t, p<O 05 vs AJr+VEGF/AMD3100
matched group

=
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Discussion
Results of the current study showed that inhalation of acrolein suppressed the
level of Flk-1+/Sca-1+ cells in the peripheral blood and prevented their
mobilization by VEGF/SDF-1. The effects of acrolein were specific because
acrolein decreased Flk-1 +/Sca-1 + cells without affecting the level of Sca-1 +cells,
indicating a unique sensitivity of this heterogeneous cell population to acrolein.
Effects of acrolein inhalation were, however, transient, and recovery in an
acrolein-free environment for 7 days led to complete restoration of the level of
these cells in the peripheral blood. Moreover, the decrease in Flk-1+/Sca-1+ cells
was associated with decreased plasma NO x level, prevention of VEGF/CXCR4induced mobilization of Flk-1+/Sca-1+ cells and inhibition of VEGF-induced Akt
and eNOS phosphorylation - a constellation of changes impinging on vascular
function and repair.

Our results also indicated that the bone marrow could be a specific locus of
acrolein action. We found that acrolein inhalation increases accumulation of
protein-acrolein adducts in the plasma and the bone marrow, suggesting that
despite its high reactivity and rapid metabolism, acrolein was delivered from the
lung into the systemic circulation and to distal vascular sites. Our previous
studies have shown that exposure to tobacco smoke or acrolein resulted in the
formation of protein-acrolein adducts in non-pulmonary sites 153,160. Thus,
acrolein appeared to cross from the lungs and directly induce bone marrow
toxicity.
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Although acrolein inhalation decreased levels of circulating Flk-1 +/Sca-1 +
cells, it increased the number of bone marrow-derived Flk-1+/Sca-1+ cells that
accumulated acLDL and were positive for Ulex lectin binding in culture. Because
the number of cells that grow out of the bone marrow on fibronectin-coated
dishes is indicative of their population in the bone marrow

159,

it appeared likely

that exposure to acrolein increased proliferation of Flk-1+/Sca-1+cells in the bone
marrow, while preventing their egress into the circulation. Alternatively,
decreased mobilization by acrolein could indirectly result in the expansion of the
bone marrow population of these cells. Nevertheless, this increase in levels of
Flk-1+/Sca-1+ cells in the bone marrow indicated that acute acrolein exposure did
not permanently impair the growth or viability of these cells but that it prevented
their mobilization from the bone marrow. We suggest that this defect could be
due to alterations in VEGF/SDF-1 signaling, but it also may be related to other
specific processes such as cell release from the bone marrow stroma by matrix
metalloproteases (MMPs), which is a NO-dependent process. Indeed, our
measurements showed that exposure to acrolein is associated with a decreased
level of active MMP-9 (73 kDa) in bone marrow lysate (Fig. Be).
Depletion of Flk-1 +/Sca-1 + cells in the peripheral blood in acrolein-exposed
mice could also be due induction of cell death. Our measurements showed that
even brief exposure (2h) to acrolein resulted in a significant increase in the
markers of cell death within the circulating Flk-1 +/Sca-1 + but not the Sca-1 + cell
population (Fig. 4). These observations reinforce the view that the Flk-1+/Sca-1+
population is uniquely sensitive to acrolein; however, perSistent suppression of
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the steady-state levels of circulating Flk-1+/Sca-1+ cells (Fig. 4) implies that the
primary defect was in the bone marrow because the depletion of these cells, due
to increased cell death or increased recruitment to sites of injury, was not
adequately compensated via mobilization from the bone marrow.

Because acrolein is one of the most reactive and toxic components of
tobacco smoke, it is not surprising that many effects we observed with acrolein
inhalation are consistent with findings of tobacco smoke exposure. Our
observation that acrolein induced endothelial injury was consistent with evidence
showing that exposure to combustion products generated by automobile
exhaust 148 or tobacco smoke 146, 147 impairs endothelial function. Previous studies
show that chronic smoking decreases the number of endothelial progenitor cells
(EPCs) and that smoking cessation restores EPC levels in human subjects 161.
The reversible effects of smoking are similar to the reversible effects of acrolein
inhalation (see Fig. 4F), as well as particulate matter (PM2.S) exposure 31 . In
contrast to chronic smoking, brief exposure to secondhand smoke increases
EPC levels 162 . Although we studied low-dose (O.5ppm) and brief (2h) exposures,
we did not observe an increase in Flk-1+/Sca-1+ cells in acrolein-exposed mice.
We speculate that the increase in EPCs upon brief exposure to secondhand
smoke may be related to other combustion products such as C0 163 , which by
inducing transient or pseudo-hypoxia could increase EPC mobilization. Yet,
inhibition of VEGF signaling by secondhand smoke exposure 164 is similar to the
effect of acrolein (Fig. 9) indicating that some of the pathological effects of
secondhand smoke could be mediated by acrolein.
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The levels of acrolein used in the current mouse exposure studies are
relevant to those encountered by passive and active smokers as well as humans
with occupations that include high level or chronic exposure to vehicle exhaust or
smoke (e.g., bus drivers, bartenders, firefighters). Given the obvious lack of
systemic toxicity (Tables 5 and 7) in mice, our observations suggested that
acrolein at environmentally relevant levels could suppress circulating Flk-1 +/Sca1+ cell numbers without inducing overt toxicity. Moreover, it is important to point
out that humans are exposed to acrolein not only from combustion, but also from
foods and beverages, which contain high levels of acrolein 165. In addition,
acrolein is generated endogenously during lipid peroxidation and via
myeloperoxidase activity at sites of inflammation 166. Hence acrolein generated
endogenously from distal inflamed tissues could also suppress Flk-1+/Sca-1+ cell
mobilization from bone marrow (and other Sites) and decrease the circulating
levels of these cells. Nevertheless, the pathophysiological significance of
acrolein-induced changes in Flk-1 +/Sca-1 +cells remains unclear and deserves
additional assessment. Previous studies show that the circulating levels of these
cells are increased acutely in response to injury and that chronic suppression of
similar progenitor cells is associated with an elevated CVD risk in humans 17. In
our analyses, we measured considerable antigenic diversity within the Flk1+/Sca-1 + population, which has characteristics of monocytes, T- and 8-cells.
However, most of these cells were CXCR4+ (Fig. 3C) and they were mobilized by
VEGF/AMD3100 which indicated that this population was likely to be recruited to
the site of hypoxic or traumatic tissue injury. Moreover, the cells were also Id 1+
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(Fig.2E). Recent work suggests that Id1 is a selective marker of EPCs because
ablation of 1d1 in bone marrow-derived cells reduces circulating EPC levels and
induces significant defects in angiogenesis as Id1 + cells are incorporated in
tumor neo-vessels 167 . Thus, the Flk-1/Sca-1 population affected by acrolein
could be important for wound healing and angiogenesis.

Wound healing is a complex process. It involves the clearance of cell
debris, regeneration of injured tissue, and the growth of new blood vessels. This
process requires the recruitment of a diverse set of progenitor cells containing
both monocytic168 and endothelial 167 characteristics, which ultimately turn into
macrophages and vascular cells to secrete proteases, cytokines and growth
factors that promote growth of tissue-resident cells. Therefore, we speculate that
suppression of this recruitable and pro-angiogenic cell population by acrolein
could lead to deficits in wound healing capacity. Future work is required to
identify the effects of acrolein on specific cell populations and how these interfere
with individual steps in the wound healing response.
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CHAPTER III
EFFECTS OF ACROLEIN ON ANGIOGENESIS

Introduction
Angiogenesis and vasculogenesis are two processes responsible for
vascular development in both adults and fetal gestation 169. The process of
angiogenesis is the development of new vessels from preexisting vessels, while
vasculogenesis refers to the development of a primitive vessel frame work by
stem and progenitor cells 170. Angiogenesis is highly regulated and controlled by a
balance of stimulators (e.g. vascular endothelial growth factor, angiopoetin-1,
and erythropoietin) and inhibitors (e.g. angiostatin, platelet factor 4, interferon-I')
of vascular formation 171. In ischemic diseases, both hypoxia and inflammation
are fundamental for the stimulation of angiogenesis 172. Several disease states
such as Alzheimer's 173, coronary artery disease 174, arthrosclerosis

175,

and

diabetes 176 have decreased angiogenesis and wound healing ability. Diabetics
often suffer from a plethora of angiogenic-related health issues retinopathy 177,
neuropathy178, nephropathy179, which can lead to ischemic ulcers and gangrene.
Aside from diabetes, active and passive smokers are subject to increased
cardiovascular health risks brought on by decreased angiogenesis 180. Studies
have shown smokers do not respond to ischemic injury or stimuli as do healthy
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non-smokers 181. Cigarette smoke exposure has been shown to decrease
angiogenesis, both in vivo and in vitro 182 . The chemical(s) found in cigarettesmoke that affect angiogenesis in active smokers and those exposed to second
hand smoke are yet to be identified. Angiogenesis was thought to develop solely
from the sprouting of local endothelial cells, however, the discovery of endothelial
78
progenitor cells (EPCs) revolutionized this dogma . EPCs are vital for ongoing
endothelial repair of damaged vessels 136. Circulating EPCs incorporate into the
sites of neovascularization and injury, improving endothelial function 183. Previous
studies have also shown active smokers have decreased numbers of circulating
EPCs 184,185, which can account for decreased angiogenesis and cardiovascular
health seen in smokers 185. EPCs are positively correlated with wound healing
and angiogenic ability186. Studies from our lab, presented in chapter II of this
thesis show EPCs (Flk-1+/Sca-1+) are decreased in a time and dose dependent
manner when mice were exposed to acrolein, much like the phenomenon seen in
chronic smokers 187.
In this study we hypothesized that exposure to acrolein could prevent
angiogenesis by preventing ischemic injury-induced mobilization of EPCs.

Methods
All Experimental procedures and protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of Louisville, and
conform to the NIH "Guide for the Care and Use of Laboratory Animals".
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Tube forming assay
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in endothelial
basal media (Clonetics/Lonza) supplemented with 20 % FBS (Invitrogen), human
endothelial growth factor (hEGF), hydrocortisone, gentamycin/amphotericin B
(GA) and bovine brain extract (BBE; SingleQuot®, Clonetics/Lonza) under
standard cell culture conditions (3rC, 5 % CO 2 ). Cells were grown in 10cm
dishes until 80 % confluent. Cells were treated with 0, 2.5, or 5mM acrolein in
5mL of Hanks Buffering solution (HBSS+) supplemented with 5IJM glucose for
30min (3rC, 5 % CO 2 ), while controls were incubated in 5mL of HBSS+ alone.
Cells were washed with warm HBSS+ and allowed to recover for 4h in fresh
media (3rC, 5 % CO 2 ). Cell were then trypsinized and seeded in a 96 well plate
(1X104 cell/well) coated with Matrigel® (BD Biosciences). Pictures were taken
every 30min of tube formation and counted for 6h using Evos® microscope.

Acrolein inhalation
Acrolein atmospheres were generated from a liquid refillable humidification tube
(LFH, Kin Tek Laboratories, La Marque, TX, USA). Acrolein emission rate of the
permeability tube was controlled by temperature, 1ppm acrolein levels were
produced by placing tube in a hot water bath at a set temperature of 50°C.
Immersion of the permeability tube in the inert gas Nitrogen allowed for trace
element of the acrolein to be emitted with high dosage accuracy. During
exposure, acrolein concentration was continuously monitored using an in-line
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photo ionization detector (ppb RAE+, Rae Industries, Sunnyvale, CA, USA)
upstream of the cage insert vapor delivery unit (Teague Enterprises, Inc.)
mounted on a standard polycarbonate rat cage (41 cm x 34 cm x 21 cm; :::::31L).
Air or acrolein was distributed through a fine mesh screen at 3 Ipm by delivery
units with a cyclone-type top that distributed air within 10% of the mean
concentration at six locations in the cage (Scheme 6). Exposure cages were
placed partially over heating pads (:::::22 °C) to allow mice to select preferable
temperature. Mice were exposed to 1 ppm acrolein for 4 days 6h/d
(99S.7±1.4ppb of) prior to induction of hindlimb ischemia (HLI) or to 2 ppm
acrolein for 4 days (2138±S.4 ppb) prior to HLI. Acrolein inhalation was continued
the day after induction of HLI in all study groups and perfusion recovery was
followed by laser Doppler imaging.
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Punch wound
Male CS7/BL6 mice at 12 weeks of age (Jackson Laboratories) were
anesthetized with Isoflurane 1-3 % in 100 % oxygen at 1 mLl minute. Mice were
shaved 24h before punch wounds were induced dorsally. A double punch wound
was made on the back between the shoulder blades using a Smm punch skin
biopsy pin (Integra Miltex Inc, York, PA, USA). (Fig. 10A)
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Figure 10

Figure. 10 punch wound model representative picture of 5mm punch wound
location
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Hind limb ischemia
Male C57/BL6 mice at 12 weeks of age (Jackson Laboratories) were
anesthetized with isoflurane 1-3 % in 100 % oxygen at 1 mLl minute. Mice were
shaved and then sensitive skin Nair (Church & Dwight Co.,Princton, NJ, USA)
applied to remove all hair on the lower limbs 24h before surgery (Fig. 11A). Mice
were anesthetized with isoflurane 1-3 % in 100 % oxygen at 1 mLl minute, the
femoral artery was ligated distal of the femoral bifurcation and proximal to the
ankle joint using 7-0 silk suture (Johnson & Johnson Co., Ethicon, Cornelia, GA,
USA), approximately 1 cm of femoral artery was excised between the ligation
pOints (Fig.12B). Skin was closed using 5-0 polyethyl (Ethicon) discontinuous
suture. Mice were given 0.05 mg/kg of buprenorphine for pain management 1
hour before surgery. Mice were allowed to recover for 24h before starting
acrolein inhalation. Mice were euthanized and changes in EPC levels were
measured after surgery by flow cytometry (see Chapter 2). Perfusion recovery
was measured on days 2, 4, 8, 12 or 18 after HLI surgery independent of
inhalation exposures.
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Figure 11
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Figure 11. Representative pictures A , shows transverse abdominal line and area
shaved then depilatory cream used for hair removal before HLI surgery,

e,

shows a representation of the HLI surgery and excision of the femoral artery and
ligation points.
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Laser Doppler perfusion imaging
Blood perfusion in the ischemic (right) and normal (left) hind limb was measured
with laser Doppler perfusion imaging (LDPI) system (PIMII, Perimed Instruments,
North Royalton, OH). Low or no blood perfusions were displayed in dark blue,
and the highest perfusion intervals were displayed in red. When laser light
penetrates the tissue under study it is scattered or partly absorbed. Some of the
scattered light returns to the tissue surface, where it is registered by a photo
detector inside the instrument head. Information sent back to the instrument head
which is read by the machine and provides information about the microcirulatory
blood flow. According to the Doppler principle, light particles which hit moving
blood cells undergo a change in wavelength/frequency otherwise known as
Doppler shift. The perfusion can be calculated because the magnitude and
frequency distribution of the Doppler shifted light are directly related to the
number and velocity of blood cells but unrelated to their direction of movement.
Perfusion data was shown as mean perfusion in volts. Mice were placed at a
depth of 12cm from the head of the PIM II on a black non-reflectant surface. The
laser was allowed to warm up for 15-20min before use. The machine was set on
high resolution, with a set threshold voltage of 6. Analysis of hind limb ischemia
data compared ischemic to non-ischemic limbs and subtraction of average
background voltage from each captured image. Data was presented as the
perfusion ratio ischemic to non-ischemic limb.
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Complete blood count
After select exposures, 100 1-/1 of blood were used for complete blood count
analysis (CBC; Hemavet 500, Coulter Counter, Oxford, CT).

Histology
Animals were anesthesized (pentobarbital; 40mg/kg). Whole thigh muscle
including adductor longus, gracilis, adductor magnus and biceps femoris of both
legs were harvested (Fig 12A-I). The gastronemius muscles were also harvested
from both ischemic and non-ischemic limbs and fixed in 10 % neutral buffered
formalin (NBF) for 24h. Fixed tissue was paraffin-embedded and cut into 51-/M
thick sections and placed on slides. Sections were stained with UE-Lectin-FITC
(1 :50; Vector Laboratories, Burlingame, CA, USA) and anti-a-Smooth Muscle
Actin-FITC (1 :250; Sigma) antibody for 1hat 37°C. Slides were washed and
nuclei were stained with DAPI (Molecular Probes, Invitrogen, Carlsbad, CA,
USA). Auto-fluorescence was quenched with 0.1 % Sudan black solution for 30
min at RT. Slides were again washed under running distilled water and cover
slipped using Slow Fade® Gold anti-fade mounting reagent (Invitrogen). Capillary
densities were calculated as the area of vessels positive for FITC-Lectin within
each field. Arteriogenesis was calculated by counting the total number of a-SMA
positive vessels within each field. Slides were examined by fluorescent
microscopy (Evos microscope 20X) in four different random fields for capillary
area calculations, while seven random fields were taken for a-SMA positive
vessels. Pictures were analyzed using Nikon Elements software.
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Figure 12

Figure 12. Representative pictures of A-I, removal of ischemic and non-ischemic
muscle that is to be fixed , processed and stained for immunohistochemistry after
HLI surgery.
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Results
Tube forming assay
To examine the effects acrolein has on angiogenesis, we first studied its
effects on the spontaneous tube formation by endothelial cells. For this, HUVECs
were cultured to 80% confluency, then treated with HBSS+, 2.5 or 5IJM of
acrolein in HBSS+ for 30min. Acrolein decreased tube formation at both 2.5 and
5IJM concentrations (Fig.13A-B). However, 2.51JM acrolein treated HUVECs
recovered to that of control by the 6h time point, while the tube formation
plateaued at 3h and never recovered after 5IJM acrolein treatment (Fig.13A-B),
showing that acrolein can affect the angiogenic ability of endothelial cells.
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Figure 13. Model of in vitro angiogenesis. A, Representative images of in vitro
tube formation after treatment with acrolein 0, 2.5, or 5IJM for 30min. B,
Quantification of tube formation following acrolein incubations. Data are
mean±SEM (n=3/group). * p<0.05 vs. control.
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Ischemic injury recovery
Ischemic injury has been shown to mobilize EPCs and play an intricate
part in wound healing and neovascularization of injured tissue 136. Our studies
have shown that acrolein decreases circulating EPCs but increases proliferation
within the bone marrow187 . Any changes in mobilization of EPCs due to acrolein
inhalation will be more apparent when EPC levels peak within the circulation after
induction of HLI. To determine peak EPC mobilization after ischemic injury, we
performed a time course study. EPCs were measured in mice without HLI, and at
2,4,8, and 12 (n=4) days after the induction of HLI. EPC levels in circulation
peaked 2 days after hindlimb ischemia, then returned baseline levels by day 12
(Fig.14B). To determine the effect acrolein has on mobilization of EPCs in
response to ischemic injury, mice were exposed to 1ppm acrolein inhalation 4
days pre-surgery and continued acrolein inhalation 2 days post-surgery (Scheme
7). Peripheral blood was drawn and flow cytometry analysis performed to
determine circulating EPC levels. EPCs were gated as previously described, Flk1+/Sca-1 + cells were gated out and plotted for CXCR4 positivity (Fig.14A).
Acrolein did not affect circulating Sca-1+/CXCR4+ cell number (Fig. 14C).
However, acrolein did decrease Flk-1+/Sca-1+/CXCR4+ cells within the circulation
(n=6,6; air 4.7±O.8 cells/IJL; acrolein 2.9±1 cells/IJL; p<O.05; n=6,6; Fig. 140). To
determine whether EPCs are in an increased proliferative state within the bone
marrow, we examined cell cycle of Flk-1+/Sca-1+ cells and found no difference
between cell cycle or total cell numbers (Fig. 14E). Stem, T-and 8-cells that
mobilized were measured to determine if any subset of Flk-1 +/Sca-1 + EPCs were
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affected. A subset within the Flk-1+/Sca-1+ cell population, CD31+/B220tCD8/CD19+/CD3+ cells were increased in acrolein-exposed mice compared with air
(air O.05%±O.005; acrolein O.08%±O.005; p<O.05; n=6,6; Fig. 14E-G). The stem
cell panel showed that two different subsets of Flk+/Sca+ cells were decreased in
acrolein-exposed mice compared with air; subset 1 B220+/CD31+/CD11b,CD115-/CD19+ (air O.08±O.002%; acrolein O.05±O.001 %; n= 6,6; p<O.05; n= 6,6;

Fig. 14H-I) subset 2 B220+/CD31 +/CD11 b-,CD115-/CD19- (air O.09±O.001;
acrolein O.04±O.001; n=6; p<O.05; n=6,6; Fig. 14H-I).
External wound healing and EPC response to ischemic injury is hampered
in smokers but is reversible with cessation of smoking 188. To further elucidate if
acrolein had any effect on superficial wound healing like what is seen in smokers,
double 5mm punch wound technique was employed. A short 2 day punch model
was used to test if acrolein inhalation affected mobilization of EPC in response to
the injury (Scheme 7). Circulating EPC levels in the punch wound model was not
significant between air-exposed and acrolein-exposed mice (Fig.1SA-D).
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Scheme 7 Two day hindlimb ischemia treatment protocol

End
Days

I,

1

2

3

I

4

Isurgery I

6

7

J

1ppm acrolein

1ppm acrolein

114

I

Figure 14

A.

~

...,.."":.
~

C"1

')

~

'\

~
§.

~

e

·s

~

~

96.5%

i

00

11

APC-FLK-1

Air
~

=---_ _----,

~

...~ .....----------,

<'1 .....-_ _

'I

~

~

'\

89.6%
: ....~..,. ···.. 1.·

APC-FLK-1

Acrolein

115

B.

c.

12

JO

"0

..
..

810

...J25
:J

:0

..
..

...Ja
:J

"";"20
C'CI

o

.,.... 6

cO

o

(1)4

u::

15

~

10

o
><
o

.,....
~

(I)

2

o

2

4

6

5
0-'-----'-----"--

a

10

12 d

A ir

E· ao

D.

Acrolein

~A i r

6

+

.... ...J
C'CI_
• :J

5

60

*

4

o~

(1)0::

+0
.... ><

3

u::

2

~O

0~

Q>
(II

ftI

40
100

J:

Q.

20

0

Air

0

Acrolein

G1

116

S

GM2

F.

oCIO
o•

CIO ' ,

lei

o0

.

0
an•.

an ' •

~
O ,~I
•
0.

,

~l

..

o•
o0.

0.

............,..-' 0.

0 ,G)

0:

.. 0

G)

,:

cl

u

Pt

10"

PE-Cy7 ·CD19

0:

, ,

It

•

PerCP.Cy5.5 CDS

117

l)

Ie:

10'

to'

,a J

PerCP.Cy5.5 CDS

G.

--+

•

0.6

n

0

0.5

CO

(,)

tnu) 0.4
+Q)

.:.::•

(,)

0.3

LL

'cf?

0.2

*

0.1
0

CD31

+

+

+

+

8220

+

+

+

+

+

+

CD8
CD19

+

CD3

+

Jl8

H.
0.6

+

DAjr

~

- Aerole n

0.5

•

CU

u

rn rn

0.4

~ =
Q)
~

-

U 0 .3

~

U.
0~

0 .2
0 .1
0

B220

+

+

+

+

CD31
CDllb
CDllS

+

+

+

-

CD19

+

+

+

119

+

Figure 14. Two day mouse model of hindlimb ischemia and characterization
and A, representative dot plots of gated FSC and PE-CXCR4 fluorescence of
Flk-1+/Sca-1+ cells that are also CXCR4 positive from air- and acrolein- treated
mice. B, Quantification of time course EPC levels per IJL after the induction of
hindlimb ischemia, measurements taken from baseline, days 2, 4, 8 and 12 from
whole blood. C, Quantification of CXCR4+/Sca-1 + cells from 2 day hindlimb
ischemia after 1ppm acrolein inhalation from whole peripherial blood. 0,
Quantification of Flk-1+/Sca-1+/CXCR4+ cells 2 days after hindlimb ischemia and
1ppm acrolein inhalation from whole blood. E, Quantification of cell cycle from
bone marrow Flk-1+/Sca-1+ cells of 2 day 1ppm acrolein hindlimb ischemia mice.

F, representative dot plots of gated FSC and gated T-cell and B-cell markers. G,
Characterization of Flk-1+/Sca-1+ cell using T and B-cell markers after 2 days of
hindlimb ischemia and 1ppm acrolein exposure. H, representative dot plots of
gated FSC and Stem cell markers I, Characterization of Flk-1+/Sca-1+ cell using
stem cell markers after 2 days of hindlimb ischemia and 1ppm acrolein exposure.
Data are mean±SEM (n=4-6/group). * p<O.05 vs. control.
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In order to determine if acrolein could affect wound closure we examined
the progression of wound healing. Double 5mm punch wounds were induced
dorsally and followed until 90% closure (Scheme 8). Wound closure of acroleinexposed mice was not significantly different when compared to air controls, in
both groups there was 90% wound closure within 10 days (Fig.15E-G).
To further determine acroleins effect on ischemia induced EPC
mobilization, a more severe model of hindlimb ischemia was employed. Mice
were exposed to 1ppm acrolein for 4 days prior to HLI surgery. After surgery
profusion recovery was followed and laser Doppler profusion images were taken
of ischemic and non-ischemic limbs on days 0, 8, 12, and 18 (Scheme 9). There
was no significance between profusion recovery of acrolein-exposed mice when
compared to air-exposed mice (Fig. 16A-B). Circulating EPC levels were
compared on day 20 of HLI, Sca-1+/CXCR4+ cells and Flk-1+/Sca-1+/CXCR4+
cells were not significant when compared with air-exposed mice (Fig. 16C-D).
For further confirmation and analysis of angiogenesis thigh and Gastronemius
muscles of both ischemic and non-ischemic legs were harvested and stained for
immunofluorescence. Tissue sections were stained for UE-Lectin to detect
capillary density and a-smooth muscle actin (a-SMA) in order to detect arterioles
(Fig. 16E). Quantification of capillary density and total number of a-SMA positive
vessels showed there were no changes in angiogenesis after hindlimb ischemia
between acrolein- and air-exposed mice (Fig. 16F-G).
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Scheme 8 Two day punch wound model treatment protocol
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Scheme 9 Ten day punch wound treatment protocol
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Figure 15. Punch wound mouse model. A, Quantification of CXCR4+/Sca-1+
cells from 2 day punch wound model after 1ppm acrolein inhalation from whole
peripheral blood. B, Quantification of Flk-1+/Sca-1+/CXCR4+ cells after 2 days
punch wound model after 1ppm acrolein inhalation from whole blood. C,
Quantification of CXCR4+/Sca-1+ cells from 10 day punch wound model after
1ppm acrolein inhalation from whole peripheral blood 0, Quantification of

CXCR4+/Sca-1+ cells from 10 day punch wound model after 1ppm acrolein
inhalation from whole peripheral blood E, Representative images of 5mm punch
wound on day 0 and 8 F, Quantification of punch wound healing every 2 days
until day 8. Data are mean±SEM (n=6/group). * p<0.05 vs. control.
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Scheme10 Twenty day hindlimb ischemia treatment protocol
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Figure 16. Hindlimb ischemia perfusion recovery and acrolein 1 ppm
inhalation. A, Representative laser Doppler measurements at days 0, 8, 12 and
18. B, Quantification of laser Doppler perfusion ratios following hindlimb ischemia
in control mice, or mice exposed to 1ppm acrolein inhalation. C, Quantification of
Sca+ cells from 20 day hindlimb ischemia model after 1ppm acrolein inhalation
from whole peripheral blood 0, Quantification of Flk-1 +/Sca-1 + cells from 20
days of hindlimb ischemia and 1ppm acrolein inhalation from whole peripherial
blood. E, Representative photographs of thigh muscle from 20 day hindlimb
ischemia mice and 1ppm acrolein exposure, stained for UE-Lectin and arterioles.
F, Quantification of capillary and, G, total a-SMA positive vessels. Data are
mean±SEM (n=6/group). * p<0.05 vs. control.
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HLI perfusion was followed for an extended time to determine the affect
acrolein potentially has on angiogenesis in vivo. Higher concentrations of
acrolein (2ppm) were used to determine if the effect is dose dependant (Scheme
11). Acrolein mice did not have hampered leg reperfusion, both air- and acroleinexposed mice had 74-76% recovery of blood flow by day 10 post-surgery (Fig.17
A-B). Circulating Sca-1+/CXCR4+ cells remained insignificant at this time point as
well. Acrolein-exposed mice had significantly decreased levels of EPCs (Flk1+/Sca-1+/CXCR4+) compared with air-exposed mice (air4.4±0.5; acrolein
1.4±0.3; n=6,6; p<0.05; Fig. 17 C-D). Complete blood counts of acrolein-exposed
mice were decreased after induction of HLI in both 1ppm/2d acrolein inhalations
and 2ppm/10d acrolein inhalations (Table 11).
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Scheme 11 Ten day hindlimb ischemia treatment protocol
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Figure 17. Hindlimb ischemia perfusion recovery of acrolein 2ppm
inhalation mice. A, Representative laser Doppler measurements at days 0, 1,3,
6, 10. B, Quantification of laser Doppler perfusion ratios following hindlimb
ischemia in control mice, or mice exposed to 2ppm acrolein inhalation. C,
Quantification of Sca-1 + cells from 10 day hindlimb ischemia model after 2ppm
acrolein inhalation from whole peripheral blood 0, Quantification of Flk-1+/Sca-1+
cells from 10 days of hindlimb ischemia and 2ppm acrolein inhalation from whole
peripheral blood.
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euthanized immediately after exposure. Units a =(Klml). b =(Mlml). c =(gldL) , d =(nglmlJ; Values are mean ± SEM; * p <0.05 vs. airmatched group; n=8 micelgroup Abbr. WBC, white blood cell; NE, neutrophil; LY,lymphocyte; MO, monocytes, RBC, red blood cell;
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Discussion
In the present study, we show that acrolein treatment decreases
spontaneous tube formation of HUVECs in vitro and acrolein inhalation
decreases mobilization of EPCs in response to ischemic injury.
Previous studies have shown that exposure to cigarette smoke decreases
circulating EPCs and decreases angiogenic recovery after induction HLl189.
Acrolein inhalations that were performed are pure exposures to acrolein,
compared to the plethora of chemicals contained in cigarette smoke, so there
cannot be a direct comparison between the results of these two studies.
However, acrolein is a highly reactive component found within cigarette smoke
and is a likely candidate for the development of vascular pathologies seen in
smokers. Indeed, in this present study we report a decrease in tube formation by
HUVECs treated with acrolein for 30min.
Angiogenesis and neovascularization are complex biologic responses and
are important processes in ischemic injury and disease 190. In both post-natal
physiological and pathological neovascularization bone marrow-EPCs play an
essential role 191. Studies have shown HLI causes mobilization of EPCs from
bone marrow to the site of ischemic injury, mobilization of EPCs is essential for
profusion recovery and limb salvage 192. Ischemic injury is a strong stimulus for
increased release of VEGF, which is a potent EPC mObilizer193 . In an attempt to
elucidate if acrolein affects mobilization of EPCs in response to ischemic injury,
mice were exposed to 1ppm acrolein for 4 days before HLI surgery and
euthanized at the peak of EPC mobilization 2 days post-surgery. Circulating
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EPCs were significantly decreased in acrolein-exposed mice, confirming a
blunted response to ischemic stimuli. Previous data have shown acroleinexposed mice have a hampered mobilization to VEGF-injections. These results
support the conclusion that EPCs are not responding to endogenous VEGF level
increases that occur after ischemic injury and thus do not mobilize 187. However,
the precise mechanism responsible for this blunted response and mobilization
remains to be elucidated.
Circulating EPC levels have been positively correlated to cardiovascular
health and increased angiogenesis with improved ischemic recovery 136. We
further investigated the decrease of circulating EPC levels and if the decrease
would affect ischemic recovery of HLI. Serial Doppler imaging showed perfusion
recovery was not affected in any HLI model; at 1ppm 20 day post-HLI nor the
2ppm 10 day post-HLI model.
In conclusion, acrolein does affect EPC mobilization in response to
ischemic injury. However, angiogenesis and reperfusion does not seem to be
affected by acrolein inhalations. Despite the negative results reported here,
acrolein could still affect angiogenic recovery after induction of HLI. The question
remains open and further research and technique development is needed to
determine the affect acrolein exposure has on angiogenesis and the
mechanism(s) involved.
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CHAPTER IV

CONCLUDING DISCUSSION
Studies presented here were designed to develop an understanding of
how acrolein, a byproduct of environmental pollutants, affects vascular health by
altering the recruitment and mobilization of endothelial progenitor cells (EPCs).

My thesis is that EPCs are sensitive targets for environmental insults, such
as acrolein, thus increasing the risk of developing cardiovascular disease
and endothelial dysfunction. Studies described here show that exposure to
acrolein by inhalation (Aim 1), prevents mobilization of EPCs by cytokine
stimulation (Aim 2). These studies also, evaluated perfusion recovery after
hindlimb ischemia in mice exposed to acrolein inhalation (Aim 3).
Results of the first set of experiments (Chapter II), show that inhaled acrolein
preferentially suppresses circulating endothelial progenitor cells (EPCs). Acrolein
specifically decreases this cell population without affecting the level of Sca-1+
cells, indicating a unique sensitivity of the EPC population to acrolein. The effects
of acrolein on this population were, however, transient, and recovery in acroleinfree environment for 7 days led to a return of circulating EPCs to baseline levels.
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The decrease in circulating levels of EPCs appears to be the result of a defect
in mobilization. Acrolein selectively suppressed basal levels of EPCs but not the
Sca-1+ cell pool indicating that it preferentially affects VEGFR-2-expressing cells.
In support of this conclusion, we found that acrolein exposure in vivo blocked
VEGF-induced phosphorylation of Akt and eNOS in isolated aorta ex vivo. The
prevention of EPC mobilization was also associated with decreased plasma NO x
levels as well, suggesting that some of the effects of acrolein on EPC
mobilization could be attributed in part to a decrease in NO production or
bioavailablity.

We also found that acrolein inhalation was associated with the accumulation
of protein-acrolein adducts in the plasma and bone marrow. This observation
suggests that despite its high reactivity, acrolein is delivered from the lung into
the systemic circulation and to distal vascular sites. Thus, acrolein appears to
cross from the lungs and directly stimulate bone marrow EPCs. Indeed, our
studies showed that bone marrow derived cells (SMOC) from acrolein-exposed
mice were more proliferative when cultured on fibronectin-coated plates.
Enhanced SMOC proliferation was observed as early as 1-2 days during initial
colony formation, which contain clusters that stained for Flk-1 +/Sca-1 + as well as
positive for acLOL uptake and Ulex lectin binding. The apparent increase in
proliferation and a decrease in circulating EPC levels indicate that acrolein does
not impair the growth or viability of these cells, but that it prevents their
mobilization from the bone marrow. We suggest that this defect may be due to
alterations in VEGF/ CXCR4 signaling but could also be related to other
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processes such as cell release from the bone marrow stroma. The specific
mechanism by which acrolein enhances BMOC proliferation but inhibits their
mobilization remains unknown and needs further investigation.

Because acrolein is one of the most reactive and toxic components of
tobacco smoke, it is not surprising that many of the effects we observed with
acrolein inhalation are consistent with tobacco smoke exposure. Our
observations that acute high level acrolein slightly injures the murine endothelium
are similar to reported effects of tobacco smoke on endothelial cells 194. The
acrolein-induced suppression of NO x could be related to diminished levels of
EPCs because both parameters returned to baseline levels following a 7 -day
recovery period. Moreover, we found that exposure to 1 ppm acrolein for 4 days
did not induce frank endothelial dysfunction although the levels of EPCs were
decreased, suggesting that decreases in the circulating EPC levels precede
endothelial dysfunction.

Humans are exposed to acrolein not only from tobacco smoke and air
pollution, but also to acrolein present in foods and beverages

165.

In addition,

acrolein is generated endogenously during lipid peroxidation and
myeloperoxidase activity at sites of inflammation 166. Our studies suggest that
acrolein generated endogenously within the bone marrow or transported to the
bone marrow from distal inflammatory processes could also suppress EPC
mobilization and decrease circulating levels of EPCs by triggering mechanisms
similar to those seen in animals exposed to inhaled acrolein.
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In this project, we characterized and counted EPCs independent of CD45+
status because the majority (>90 %) of EPCs express CD45 antigen. We
reasoned that because of acrolein's propensity for targeting the endothelium,
acrolein exposure could result in injury and mobilization of EPCs for repair.
Chronic smoking is associated with a decrease in EPC levels in humans similar
to the suppression of EPCs in blood that we have reported 195 . Hence, these
finding suggest a novel connection between a specific component of cigarette
smoke, acrolein, and air pollution generated from the combustion of organic
materials and provide new insights into the mechanisms by which exposure to
these pollutants can increase the risk of developing cardiovascular disease.

We next wanted to determine the effects acrolein had on vascular
regeneration using in vivo and ex vivo approaches. Our cell culture studies
showed that acrolein treatment decreased spontaneous tube formation of
HUVECs seeding on Mitragel. To further elucidate the effects acrolein on
angiogenesis and profusion recovery we studied two models of wound healing,
i.e. ,the punch model and hindlimb ischemia . However, we found that the
progression of wound healing in these models was not affected by acrolein
exposure-. We reasoned that the punch wound model is not a severe model of
ischemia and does not elicit the hypoxic response necessary to significantly
increase plasma VEGF and increase circulating EPC levels to the extent of HLI
model 196 . Studies have shown VEGF exerts dominant functions during
angiogenesis and is necessary for EPC mobilization from the bone marrow.
Hindlimb ischemia is also a potent stimulator of VEGF release and mobilizes
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EPCs into the circulation almost 13 fold over baseline 197. We found that with the
induction of hindlimb ischemia, circulating EPC levels peak on day 2 of ischemic
injury. However, after day 2 of HLI mice exposed to 1ppm acrolein had
significantly decreased circulating EPC levels. This data suggests exposure to
acrolein prevents EPC mobilization due to hindlimb ischemia perhaps by
preventing the stimulatory effects of endogenous VEGF on the mobilization of
EPCs from the bone marrow in response to HLI. To develop these observations
further, an extended 1ppm acrolein exposure was carried out to determine if
decreased circulating EPCs affected angiogenesis and reperfusion recovery after
HLI . Our results showed that acrolein exposure did not affect circulating EPC
levels or the rate of recovery of tissue perfusion. Hence, no determination could
be made if EPCs affected perfusion recovery because EPC levels did not differ
between control and inhalation animals. To examine whether the effects of
acrolein on angiogenic recovery might be a dose-dependent phenomena,
acrolein exposure levels were increased to 2ppm. Our results with the higher
dose showed a trend towards decreased perfusion recovery of 2ppm acroleinexposed mice, however this did not reach statistical significance. Circulating
EPCs were also not significantly different in HLI of 2ppm acrolein-exposed mice
when compared with air-exposed mice. Both 1ppm and 2ppm HLI studies
produced negative results, however, in chapter III EPC levels were shown to
return to baseline by day 12 of HLI. EPCs may become desensitized to
mobilization stimuli after a period of time or EPCs mobilization could become
exhausted after prolonged ischemic stimulation. Further research is needed to
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determine the possible detrimental effects that acrolein could have on
angiogenesis, vascular repair and how this could potentially effect wound
healing.

Overall, the data presented here support the global hypothesis that EPCs
are a sensitive target for acrolein, thus increasing the risk for developing
cardiovascular disease and endothelial dysfunction.
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Part II: Research
My research at the University of Louisville was initiated as an attempt to
understand the link between environmental pollution and increased mortality
rates. Previous studies have shown a strong negative correlation between
pollution and developing heart disease, diabetes, and decreased wound healing
ability, however the physiologic reason behind this still remains a mystery. In my
research I studied adult endothelial progenitor cells (EPCs), a small subset of
cells that have stem cell and endothelial cells properties and heal damaged
endothelium. There is also a strong negative correlation between the number of
circulating EPC and the risk for developing heart disease, diabetes, and
decreased wound healing. Little has been done with the characterization of EPC
in mice models, so our lab has done an extensive set of cell markers by flow
cytometry and developing the first heirarchy of mouse EPCs. My main field of
study came to be EPC and how they were affected by acrolein. Acrolein is a
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highly reactive unsaturated aldehyde present in all forms of pollution in high
amounts. In my research I have found acrolein inhalation does indeed decrease
circulating endothelial cells and hinders angiogenic assays in vitro, in a time and
dose dependant manner. With this knowledge our lab can now began to unravel
the mystery behind pollution and high mortality rates, thus decreasing or even
preventing pollution related deaths.
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